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Healthcare cost are increasing and are already very high worldwide and in Hungary. In 
Hungary, per capita health expenditure is below the EU average. In Hungary, per capita 
health expenditure was 1996 USD in 2017, in the same year it was 5848 USDin Germany, 
5264 USD in Sweden, and 5025 USD in Denmark. (OECD, 2020). Hungary spent 7.4% 
of its GDP on health care, which was also below the EU average of 9.9% 
(EurópaiBizottság, 2017, Eurostat, 2019).  
The economics of chronic diseases are issues of great importance from the point of view 
of health policy and financing, as these diseases cause significant burden not only for the 
individual, the family, but on a societal level too. 
Healthcare needs are similar to that of high-income countries. In Hungary, life expectancy 
was 76.2 years in 2018, healthy life expectancy was 61.1 years, while life expectancy in 
Germany was 81.0 years, and in Austria 81.8 years. Healthy life expectancy was 65.8 
years 56,9 years in 2018 (Eurostat, 2018b, Eurostat, 2018a). 
Knowledge of costs and outcomes (disease, disease burden), analysis of the cost-
effectiveness of therapies is essential information for the financier and health policy-
maker in order to achieve sustainable financing in health care sector and create the 
optimal allocation of resources. 
 
The identification and measurement of different costs in chronic diseases, as well as the 
analysis of outcomes including the quality of life of patients (and family members, 
carers), contributes significantly to the disease burden assessment in financing decisions. 
In Hungary, such data are not available from the databases of the financier, the National 
Health Insurance Fund Management (NHIFA). 
 
The importance of health economics analysis, similarly to other developed countries, is 
growing in Hungary. This is due to the fact that an increasing part of the health care 
budget is allocated, in accordance with legal requirements, taking into account the results 





The economics of chronic diseases is an extremely important issue from the point of view 
of health policy, public health resource allocation and financing, as the disease burden 
and costs are significant and constantly increasing not only at the individual, family, but 
also on a societal level. Information on costs and outcomes, analysis of the cost-
effectiveness of therapies is essential information for the financier and health policy 
decision-maker in order to achieve sustainable financing in healthcare sector. 
The identification and measurement of different costs for each chronic disease, as well as 
the analysis of non-therapeutic and non-therapeutic outcomes, including the quality of 
life of patients (and family members, carers), contributes significantly to the disease 
burden assessment. In Hungary, such data are not available from the databases of the 
financier, formerly the National Health Insurance Fund, currently the National Health 
Insurance Fund Manager (NHIFA). 
The importance of health economics analysis, like in other developed countries, is large 
and constantly growing in Hungary. The reason for this is that an increasing part of the 
health care budget is allocated in accordance with legal requirements, also taking into 
account the results of health economics analysis (Gulácsi et al., 2014b). The most 
important methods are costing, disease burden, cost-effectiveness and budgetary impact 
analyses. 
These calculations require valid, standardized, periodically updated, and available cost 
data (unit costs) and outcome information. It is very important that in the course of 
analyses and health economics calculations, these data are used in the same way in all 
cases, regardless of whether they are made in the competitive or public sector 
(pharmaceutical distributors or AEK), as the results are only in this case. can be 
compared. 
In the case of health resource allocation decisions, budgetary effects and cost-
effectiveness results are compared, benefit-sacrifice costs are examined, and accordingly, 
the usability of the data without meeting the comparability requirements is severely 
limited. 
Examples of such unit costs are the cost of one GP visit, the cost of an ambulance service 
for 1 km, the cost of 1 hour of informal care, the cost of an average hospital admission, 
the cost of being absent from work and the productivity loss during work due to illness. 
Cost-effectiveness calculations often require knowledge of costs associated with a disease 
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that can be avoided in whole or in part as a result of the use of a particular drug. For this, 
it is necessary to know, for example, the costs of stroke, myocardial infarction, 
rheumatoid arthritis and other diseases in Hungary. 
The lack of a database summarizing costs and unit costs for a given country (called the 
Hungarian cost library) as we can see in Hungary, makes it very difficult to standardize 
cost calculation methods and contributes to different unit costs in different analysis. Often 
it is not even possible to clearly state which unit costs were used for the cost calculation 
and the health economics analysis. Because of this, the validity of the results is unknown 
and comparability is very uncertain. 
One important area is the inclusion (into financing) of new therapies in the social 
insurance system, during which it is absolutely important to assess the costs of the given 
health technology (prevention, screening, diagnosis, therapy) and the potential benefits 
of its use. 
Conducting cost-effectiveness and budget impact analysis prior to health policy and 
financing decisions is required by all European (and other developed countries) 
legislation. Mandatory consideration of cost-effectiveness aspects in health policy 
decisions is also regulated in a decree in Hungary (7/2016. (III. 30.) EMMI rendelet) „a 
biztonságos és gazdaságos gyógyszer- és gyógyászatisegédeszköz-ellátás, valamint a 
gyógyszerforgalmazás általános szabályairól” (EMMI, 2017). Local cost data must be 
used  for the analysis, as cost data from other countries cannot be transferred to Hungary, 
due to very significant differences in unit costs, health financing and healthcare practices. 
(Brodszky et al., 2019).  
Cost-of-illness (COI) studies provides information on the economic burden of a particular 
disease, from an individual, financial, or societal perspective. Their aim is not only to 
identify the costs associated with the disease, but also to determine the overall societal 
burden, including healthcare and non-healthcare costs, thus helping to understand the 
significance of a given health problem and identify key cost items and cost structure 
(Drummond et al., 2005). As a result, cost of illness studiesare extremely important and 
contribute to supporting decision-making processes (Boncz et al., 2006). The growing 
role of HTA in the countries of the region over the last decade makes it even more 
necessary to use reliable, local (country-specific) cost data (Gulácsi et al., 2014b, Feig et 
al., 2017, Boncz et al., 2006).  
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There is no golden standard for conductiong costing and cost of ilness analysis (Larg et 
al., 2011, Jacobs et al., 2005, Raspe et al., 1998). Alongside to the harmonization of 
different methodologies, it is becoming an increasingly important aim to establish 
comparability; currently, different research in many cases uses different structures, 
methodologies, perspectives, and costing approaches (Angelis et al., 2015, Onukwugha 
et al., 2016).  
In the case of chronic diseases, not only the presence of direct health care costs, but also 
the direct non-health care and the indirect costs can cause significant burden on a societal 
level. Previous studies show that in many chronic diseases, informal care is a major factor 
inn patient care. In addition to current demographic trends, the use of informal care is 
expected to become an increasingly common. Informal care is the care provided to 
patients and those in need, outside the formal, state-funded framework of health care and 
social care, which is not reimbursed. Patients receive help from family members, those 
living in the same household as them and friends to carry out their daily tasks (dressing, 
bathing, eating, housework), informal helpers shop, buy prescription medications, and 
arrange other matters, and take the patient to health care facilities if needed. Even on 
acute conditions, the help provided by family members may become necessary 
(childbirth, postoperative periods), but in chronic diseases, long-term informal assistance 
may be even more important. Informal care takes a lot of time of the helpers (informal 
caregivers) and many of them drop out or miss work, which is why informal care is 
becoming an increasingly important field nowadays  (Gulácsi et al., 2012, Beretzky et al., 
2017, Zemplenyi et al., 2016). In addition, informal care can have a negative impact on 
the health and quality of life of informal carers and can lead to significant costs (Krol et 
al., 2015). The time spent on informal care and the associated costs can be considered as 
a disease-related cost, assuming that in its’ absence it would be necessary to replace this 
care activity with formal health and social care. 
However, informal care can in many cases be underestimated if its costs are ignored in 
the economic evaluation of health interventions (Krol et al., 2015), therefore, the 
inclusion of informal care in health economics analysis of chronic diseases can influence 
their outcomes and contribute to better decision-making in policy-making (van den Berg 
et al., 2004). Access to informal care depends on a number of factors, such as the socio-
demographic attributes of the society, so in addition to knowing country-specific data, we 
get a more comprehensive picture of the burden of disease. 
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In chronic illnesses that last for decades, informal care is even more important. This has 
an important role to play in aging societies, as life expectancy has increased and is 
increasing significantly, as people live longer and longer with more or less reduced self-
sufficiency and therefore need the help of others temporarily or permanently (Verbakel 
et al., 2017), In 2015, the proportion of people over the age of 65 among the population 
of the EU28 Member States was 18.9%, while in Hungary it was 17.9% (Eurostat, 2017). 
The aging of the “baby-boomer” age groups also significantly increases care needs. 
However, the need for informal care is not limited to the elderly. An increasing number 
of children and young adults are living with severe chronic illness and require informal 
care. Examples are the so-called rare diseases, in which the number of patients in each 
disease is not high, but hundreds of thousands of patients are affected by more than a 
thousand different rare diseases (Cavazza et al., 2016b, Kuhlmann et al., 2016, Iskrov et 
al., 2016, Lopez-Bastida et al., 2016a, Péntek et al., 2016c, Cavazza et al., 2016a). As a 
result of the use of increasingly effective medical technologies, the life expectancy and 
number of people living with chronic diseases in developed countries, including Hungary, 
will increase significantly. This trend is also well observed in European countries, where 
the incidence of activity-limiting chronic diseases has increased significantly. These 
include dementia, osteoporosis, cardiovascular disease and cancer. 
Nowadays, the cost of informal care for people with chronic illnesses is significant, in 
most cases it exceeds the direct health care costs. (Hoefman et al., 2013, Eurostat). These 
costs have been in exceeded of the costs of the insurance and state-funded health care 
sectors in the United States decades ago. (Arno et al., 1999). Informal care can to some 
extent replace insurance or state-funded health / social care, thereby reducing these health 
care expenditures (Bremer et al., 2015, Boncz et al., 2006). However, it is also an 
important aspect that the health of informal carers sometimes deteriorates and their ability 
to work decreases (Colombo et al., 2011). With the current demographic trends 
continuing, it is predictable that the need for informal care and the resulting costs will 
continue to increase significantly (Vlachantoni et al., 2013, KSH, 2013). 
The burden of chronic diseases is increasing, as these conditions are the main causes of 
health and health-related quality of life decline, and a significant part of health 
expenditure is also attributable to them (Bauer et al., 2014). Measuring health-related 
quality of life in chronic diseases helps to assess the effectiveness of a given therapy and 
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provides information on potential health gains. This information can help optimize 
resource allocation and help decision-making. 
 
Quality of life is a multidimensional concept which includes of health-related quality of 
life. There are a number of diseases that do not significantly affect life expectancy but 
have a negative impact on a patient’s quality of life. Therapies for the treatment of 
diseases also have an impact on quality of life in many cases, and without measuring this, 
their real benefits cannot be estimated. Measuring health-related quality of life 
contributes to the identification of needs, the description of health conditions, and helps, 
to make choices between different therapies, thereby contributing to the efficiency of 
resource allocation. Nowadays, measuring the quality of life is becoming more and more 
important, as more and more people live with chronic diseases for a longer period of time, 
which is why public health programs are paying more and more attention to the quality 
of life. 
 
The field of research is of key public policy importance. Within a country, groups of the 
population with different demographic and socio-economic characteristics have different 
health needs and may receive different health care, the assessment of which is a 
significant issue.  
 
Stiglitz highlights the importance of state intervention in health care. Health policies aim 
to develop a health system that is health-oriented, seeks to influence socio-economic and 
health determinants of health, provides equal opportunities, is effective, can be financed, 
and seeks to maximize health status with the limited resources available (Stiglitz, 2000). 
 
In the field of healthcare, a number of market failures are emerging, the presence of which 
also justifies the need for public intervention: the problem of public goods, externalities, 
information asymmetries, limited competition and the meritorical nature of goods 
(Stiglitz, 2000). 
Information asymmetries are significant in the field of health care, and health care 
recipients must rely on the knowledge and decisions of the physician and other health 
care professionals. However, the physician does not have complete information in all 
areas, for example, they are aware of the results of the patient's laboratory tests, but does 
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not necessarily know the patient's general health, quality of life, well-being or their impact 
on social abilities. 
Reducing information asymmetries is also hampered by the difficulty of comparing 
services (cost, quality, efficiency). In the healthcare sector, this comparison is not 
feasible, as there are too many different interventions, hospitals and doctors present, for 
example, a hospital may be excellent in performing certain interventions and weak in 
others (Stiglitz, 2000).  
The need to reduce information asymmetry makes it difficult to compare services (cost, 
quality, efficiency). In the healthy sector, this comparison is not applicable, as there are 
too many different interventions, the presence of a hospital and a doctor, in one hospital 
it is necessary to perform excellence in performing it, in another intervention it may be 
weak. 
In addition, competition between hospitals is limited, and good and efficient providers 
are not expected to crowd out the weaker ones to gain a competitive advantage. In most 
towns, even large ones, there is only one hospital (Stiglitz, 2000). „The patient relies on 
the doctor's judgment as to what medication to take, whether it is advisable to undergo 
surgery, and so on” (Stiglitz, 2000, p315.). 
As Stiglitz puts it, “Incomplete information reduces the effective level of competition”. 
"At the same time, the heterogeneity of medical services makes price and quality 
comparisons very difficult, and therefore not conducive to the effective dissemination of 
information." (Stiglitz, 2000, p316.) and "The practice of the medical profession is 
probably consistent with the fact that competition is inevitably limited due to imperfect 
information." (Stiglitz, 2000, p316.). Stiglitzs also highlighted that „Most hospitals are 
non-profit institutions”  (Stiglitz, 2000, p316.).  
Today, this is why governments and insurers try to measure not only this (quality, cost), 
but also the condition of the patient at the time of admission and discharge (by generic 
and disease-specific measures). 
Increasingly, funders do not want to “buy” health services but “results,” which can be 
expressed as health gains. 
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Decision-making is partly the job of doctors and health-care professionals, but they also 
have to account for health gains. In part, the decision is made by the financier of a given 
country, by determining what to finance. 
It is noteworthy that excessive health care spending can be inadequate and can cause 
harm. The results of one study showed that the probability that a child’s tonsils were 
removed ranged from 7 to 70% in Vermont, USA. This phenomenon, called over-
management, is also characteristic of Hungary, one of the consequences of information 
asymmetry, which the OECD has repeatedly pointed out in its country report (OECD, 
2019). 
The two most significant elements of health financing are resource creation and resource 
allocation, i.e. the mechanisms and methods through which resources are used (Stiglitz, 
2000). In the existence of a publicly funded care system, a significant question is how 
health services are financed by the state, i.e. the ‘public’, and its members, who maintain 
the health care system through their contributions. 
At the moment, in Hungary, short-term and long-term public funding decisions related to 
health care are not routinely collected and data of adequate quality and quantity are not 
available. 
The dissertation reports on the results of different health economics researches, 
accordingly it is characterized by significant methodological heterogeneity, as different 
researches often require the application of very different methodologies. 
 
The structure of the dissertation is as follows: 
 
Starting from Chapter 4 of the dissertation, the member in the second position (local 
value) of the numbering in each chapter indicates the description of a larger research 
circle. Accordingly, starting in Chapter 4, subsections 4.1, 5.1, 6.1, and 7.1 present the 
objectives, methodology, results, and discussions of the same research. 
"1." in the second position of the chapter numbering marked subsections discuss research 
on quality of life measurement. The subchapters, denoted by a number with a third local 
value, denote individual researches in the field of quality of life measurement. 
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Comparison of four different EQ-5D-3L value sets (1)1 (Zrubka et al., 2019), a detailed 
analysis of the DLQI questionnaire (2)2 (Rencz et al., 2018),  the anlysis of the health 
state and productivity of the Hungarian general population (3) (Péntek et al., 2020)3, and 
the characteristics and determinants of informal care (4) (Beretzky et al., 2017)4.  
In the second position of the chapter numbering "2." the topic of the marked subchapters 
is costing in health care; this sub-chapter also includes further research, which has been 
separated by numbers in the third local value of the chapter numbering: measuring the 
costs of informal care (1) (Beretzky)5, cost of illness studies in the Central Eastern 
European region (2) (Brodszky et al., 2019)6, and the Hungarian cost library (3).  
The structure of the dissertation is displayed on Figure 1. (Figure 1.) 
                                                             
1 The corresponding subsections are based on the following publication: Zrubka Zs, Beretzky Zs, Hermann 
Z, Brodszky V, Gulácsi, L, Rencz, F, Baji P, Golicki D, Prevolnik-Rupel V, Péntek M (2019): A 
comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 
18 chronic diseases. European Journal of Health Economics 20, Suppl. 1, pp. 119-132. 
2 The corresponding subsections are based on the following publication: Rencz F, Poór AK, Péntek M, 
Holló P, Kárpáti S, Gulácsi L, Szegedi A, Reményik É, Hidvégi B, Herszényi K, Jókai H, Beretzky Zs, 
Brodszky V (2018): A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases 
in treatment decisions. Journal of The European Academy of Dermatology and Venereology, 32, 5, pp. 
783-790. 
3 The corresponding subsections are based on the following publication: Péntek M, Beretzky Zs, Brodszky 
V, Szabó, A. Kovács, L. Kincses, Á. Baji P, Zrubka Zs, Rencz F, Gulácsi L: A magyarországi lakosság 
egészséggel összefüggő munkaképessége: keresztmetszeti reprezentatív felmérés a Munkaképességre és 
Tevékenységcsökkenésre vonatkozó kérdőívvel. Orvosi Hetilap, accepted for publication 
4 The corresponding subsections are based on the following publication: Beretzky Zs, Péntek M (2017): 
Informális ellátás és meghatározó tényezői krónikus betegségekben: magyarországi kutatások 
összehasonlító elemzése [Characteristics and determinants of informal care in chronic diseases in Hungary: 
a comparative analysis] Orvosi Hetilap, 158, 52, pp. 2068-2078. 
5The corresponding subsections are based on the following publication: Beretzky Zs: Az informális ellátás 
költsége krónikus betegségekben: magyarországi kutatások összehasonlító elemzése. Köz-Gazdaság, 
accepted for publication  
6 The corresponding subsections are based on the following publication: Brodszky V, Beretzky Zs, Baji P, 
Rencz F, Péntek M, Rotar A, Tachkov K, Mayer S, Simon J, Niewada M, Hren R, Gulácsi L (2019): Cost-
of-illness studies in nine Central and Eastern European countries. In: European Journal of Health 



































analysis of ’not 
relevant’ 





A Comparison of 
European Polish, 
Slovenian and British 
EQ-5D-3L value sets 
using a Hungarian 















determinants of informal 
care in chronic diseases 
in Hungary
Cost of informal 








In this chapter, I summarize the most important theoretical concepts and 
methodological background of the research applied and planned in the 
dissertation. 
In our research, we examined the reduction in quality of life and costs caused by 
diseases, as well as the health gains (disease-specific and generic measures), cost-
effectiveness, and budgetary impact of therapies. Decreased quality of life (and 
its consequences, social impact) is the burden of disease caused by the disease, 
which can be at least partially avoided by using appropriate therapies. Together, 
these are necessary for health economics analysis. As different theoretical 
concepts and methodologies have been applied, this may also appear to be a 
methodological heterogeneity, although the full range is required for the studies. 
The following section presents the background of these studies and the 
methodological concepts used in this thesis. 
 
2.1. Health-related quality of life 
 
In addition to life expectancy, quality of life is the most important indicator in 
evaluating the consequences of diseases and the benefits of therapies. Quality of 
life is influenced by a number of factors, in this case we focus on discussing and 
researching health-related quality of life related. 
General and disease-specific measures are used to measure health-related quality 
of life. 
The most widely used generic quality of life measure in most languages in the 
world is the EQ-5D questionnaire and a disease-specific quality of life 




Generic measures enable comparison of changes in quality of life between 
different diseases and to calculate cost-effectiveness as described in this chapter, 
so the results are also useful for health policy decision makers. 
Disease-specific measures are suitable for measuring disease severity and 
monitoring the effect of therapy, and are accordingly used in clinical practice. The 
results of these measures are used to determine the indication for (often very 
costly) therapies (when the patient can receive therapy). Therefore, these medical 
decisions are also resource allocation decisions (since the doctor makes public 
vouchers from the social security fund with the indication decisions), so they are 
also of great economic importance. 
 
2.1.1. The EQ-5D questionnaire 
 
The most commonly used questionnaire to measure health-related quality of life 
is the EQ-5D questionnaire (Brazier et al., 2019). The descriptive system focuses 
on five dimensions of health: Mobility, Self-care Usual activities, Pain/discomfort 
and Anxiety/depression. In each dimension, there are three categories that 
respiondents can choose from, representing: no problems - 1, moderate problems 
2; severe problems- 3. Respondents are asked to indicate for each dimension the 
level of problem that best describes their current health status. The ’21112’ EQ-
5D profil signifies a health stat with moderate problems in Mobility and 
Anxiety/depression. (EuroQolGroup, 1990). The EQ-5D-5L version has 5 
choices for the fivre different level of problems, resulting in 3125 (37) different 
health staes (Herdman et al., 2011). The EQ-5D questionnaire includes a visusal 
analogue scale, the so-called EQ VAS, where respondents can indicate their 
current health state beetween 0 (worst imagineable health state) and 100 
(complete health). To each EQ-5D a utility value can be attached. EQ-5D-3L 
value sets have been developed in many different countries, and are based on 
preferences of the general population, they were created using direct methods 
such as time trade-off, visual analogue scale, standard gamble, SG), or discrete 
choice experiment.  The country specific value sets reflect the characterics of the 
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given country and the preferences of the general population. Previous studies 
suggest that the differences are attributable to socio-demographic and cultural 
factors (Devlin et al., 2017). The studies presented here in this thesis used the UK 
(United Kingdom) EQ-5d value set, as a Hungarian value set was not available at 
the time of the research (Baji et al., 2015). The Department of Health Economics 
used the EQ-5D questionnaire in a number of previous studies (Péntek et al., 
2014, Pentek et al., 2013, Péntek et al., 2012c, Péntek et al., 2012a, Péntek et al., 
2016c, Péntek et al., 2007, Rencz et al., 2014, Rencz et al., 2015c, Balogh et al., 
2013, Bernert et al., 2009, Brodszky et al., 2009, Brodszky et al., 2010d, Batog et 




In health economic analysis utility is used to measure the preference for a specific 
health condition or outcome. The utility of total health is considered to be 1, and 
the utility value of 0 can be associated with the state of death. “Worse than death” 
conditions have a negative utility value. Utility can be measured using direct and 
indirect methods. Direct methods are standard game (SG), visual analog scale 
(VAS) and time trade-off (TTO). The tools of indirect utility measurement are 
e.g. EQ-5D or the Short-Form 6D (SF-6D) questionnaire. 
 
2.1.3. Disease specific questionnaires: Dermatology Life Quality Index 
 
Quality of life can be measured not only with general but also with disease-
specific questionnaires. The Dermatology Life Quality Index (DLQI) 
questionnaire has 10 items and respondents can choose answers corresponding 
with a score between 0 and 3 for each question, depending on how much the skin 
problem affected the patient's quality of life in the week before completion (Basra 
et al., 2008). The 10-item questionnaire covers six areas of health-related quality 
of life: symptoms, daily activities, leisure, work and education, personal 
relationships, and treatment. Each question was scored on a four-point scale (0 = 
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“not at all”, 1 = “slightly”, 2 = “fairly”, 3 = “very much”). In addition, for eight 
questions, the respondent has the option to indicate a “not relevant response” 
(NRR) answer, which has a value of 0, similar to the “not at all” answers. The 
total score of each element can be between 0 and 30, where a higher value can be 
associated with a greater deterioration in quality of life (Basra et al., 2008). 
The NRR response option appears in 80% of the questions, which is unusual for 
a short questionnaire, however, their examination is rare and inconsistent in the 
literature. The majority of DLQI studies do not report the incidence of NRR 
responses, however, studies from several countries have reported a large number 
or almost no NRR responses (Ferraz et al., 2006, Hahn et al., 2001, Herédi et al., 
2014). 
 
2.1.4. The concept of quality adjusted life years 
 
One of the most commonly used measure of health outcomes, the Quality 
Adjusted Life Year (QALY) (Rios-Diaz et al., 2016). QALY expresses both 
length of life and quality of life with a value of utility. The state of perfect health 
is denoted by 1 and the state of death by 0. 
Health conditions considered worse than death are described by negative 
numbers. The QALY does not differentiate between the severity of each condition 
or the differences in the individuals studied and does not differentiate between 
length of life and quality of life. 
 A year spent in complete health is considered equivalent to ten years in a state of 
0.1 quality. If we want to express an improvement in health, we can observe that, 
for example, from 0.3 to 0.5 at the age of 30, and from 0.8 to 1.0 at the age of 60 
(Gulácsi et al., 2012). 
Utility values are assigned to each health condition by measured population 
preferences. These utility values are determined by the population or groups of 
patients based on imagined or experienced health conditions (Brazier et al., 2018).  
Health-related utility can be measured by both direct and indirect methods. Direct 
methods measure utility by evaluating specific disease descriptions, and indirect 
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methods by evaluating conditions that can be described by general quality of life 
questionnaires. What the two methods have in common is that it evaluates the 
utility of a particular state with a particular utility value (Brazier et al., 2019). 
 
2.1.5. Health state and well-being 
 
In addition to quality of life measures, the health and well-being of a given patient 
can be measured in a number of other ways. The questionnaires and methods that 
were included in our research are briefly presented below. 
 
2.1.5.1. Minimum European Health Module (MEHM) 
 
The Minimum European Health Module (MEHM) consists of three general 
questions. The respondent rates the present health on a five-point scale (Very 
good / Good /Fair / Bad / Very bad). It states whether you have a chronic illness 
for at least 6 months (Yes / No) and whether you have a health problem for at 
least 6 months (severely limited / limited, but not severely / not limited), the latter 
measure being the so-called Global Activity Limitation Indicator (GALI) 
(Eurostat, 2013, Eurostat, 2019). 
 
2.1.5.2. ICECAP-A and ICECAP-O questionnaires 
 
The ICECAP-A (ICEpop CAPability measure for Adults) and ICECAP-O 
(ICEpop CAPability measure for Older People) are tools for measuring skills and 
experienced well-being. The standards have been developed based on Amartya 
Sen’s approach, which bases the well-being of individuals on their ability to 
perform activities that are important in their lives. Both questionnaires can be 
used as a yardstick in health economics analyses. The ICECAP uses a broader 
interpretation of well-being and does not focus only on the health dimension. The 
ICECAP-A questionnaire focuses on five main areas: Attachment (an ability to 
have love, friendship and support), Stability (an ability to feel settled and secure), 
Achievement (an ability to achieve and progress in life), Enjoyment (an ability 
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to experience enjoyment and pleasure), and Autonomy (an ability to be 
independent). By completing the questionnaire, the respondent can choose from 
the four possible answers the statement that best describes his situation. ICECAP-
O allows respondents to choose between the four answers in the dimensions 
Attachment (love and friendship), Security (thinking about the future without 
concern), Role (doing things that make you feel valued), Enjoyment (enjoyment 
and pleasure) and Control (independence). The ICECAP score can range from 0 
to 1, with a scale of 0 indicating a complete lack of skills (Al-Janabi et al., 2012) 




Assessing the burden of disease, determining the costs of diseases and health care, 
identifying relevant resources, measuring their use, and determining their value 
are the basis for costing. A significant choice in costing is the choice of 
perspective. The identification and measurement of data on the disease burden, 
disease cost, and cost of therapies for each disease is of paramount importance 
today, as it provides input data for health economics analyses. In order to make 
optimal health policy decisions and allocate resources and strive for sustainable 
financing, it is necessary to know detailed, country-specific cost data on the costs 
of individual diseases and therapies. Costs can be classified into direct health care, 
direct non-health care and indirect cost. 
 
2.2.1. Direct healthcare costs 
 







2.2.2. Direct non-healthcare costs 
The direct non-healthcare costs include the cost of informal care, cost of travelling 
to receive health care services or remodelling of the patient’s apartment due to 
changed needs. 
 
2.2.2.1. Informal care  
 
Informal care is care provided by non-professional caregivers, outside of the 
organized health insurance founded healthcare system. Informal care is not paid, 
but can amount to significant burden in chronic conditions. The informal care 
need is quite significant in certain chronic diseases; it can amount to a large 
percentage of the overall cost. Previous studies show that patients suffering from 
Parkinson’s disease or dementia require more than 12 hours of informal care 
weekly (Zrubka, 2017, Beretzky et al., 2017). The role of informal care is ever 
increasing as formal healthcare is not aiming to provide long term care for 
patients. (Zrubka, 2017, Beretzky et al., 2017), and patients also prefer care 
provided in their own home by relatives in many cases. 
The cost of informal can be estimated with several different methods. Most 
commonly used is the market price and the opportunity cost methods. The former 
uses the market price of such service, the latter uses the wage of the informal carer 
that could be realized if the carer would do payed work in instead of providing 
informal care (Zrubka, 2017, Beretzky et al., 2017, Gulácsi et al., 2012). 
 
2.2.3. Indirect cost 
 
Indirect cost includes the cost of the patients’ time and productivity losses 
experienced by the patient.  Missing time from payed work or experiencing lower 
productivity while working is mainly measure by two methods: the human capital 





Absenteeism expresses a loss of labour productivity due to absence from work 
due to health reasons (sick pay, long-term absence due to illness, disability). 
Presenteeism 
Decreased productivity may occur not only due to absence from work, but also 
due to decreased productivity at work due to illness, as expressed by 
presenteeism. 
 
2.2.3.1. Measuring productivity loss): Work Productivity and Activity 
Impairment (WPAI) questionnaire 
 
Productivity costs can be measured using an internationally validated 
standardized questionnaire. The Work Productivity and Activity Impairment - 
General Health (WPAI-GH, “WPAI”) is a questionnaire designed to assess 
disability due to health problems (physical and mental problems or symptoms) in 
paid and unpaid work. The questionnaire is suitable for measuring both 
absenteeism and presenteeism, as well as its barriers to unpaid work and other 
activities. 
The questionnaire consists of six questions. Respondents must first indicate 
whether they are currently doing paid work (Q1). The following section (Q2-Q5) 
is only relevant for participants who do paid work. The number of hours absent 
from work due to health (Q2) and other reasons (Q3) is asked. Respondents 
should then indicate how many hours they actually worked in the last seven days 
(Q4). The rate of loss of labour productivity experienced at work is measured by 
the questionnaire on an 11-point scale (0: not affected, 10: completely prevented). 
The last question (Q6) concerns the extent to which the respondent’s health 
problems affected his or her daily activities. This question also uses an 11-point 
rating scale (0: not affected, 10: completely prevented). 




Abstenteeism: Absence from work due to health condition: Q2/(Q2+Q4) 
Presenteeism: Decreased productivity due to health status at work: Q5/10 
Total productivity loss while working (%): Total labour productivity loss due 
to health:  
Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))) x(Q5/10)] 
Productivity loss in other activities (%): Decrease in productivity due to health 
status experienced in everyday activities: Q6/10 
 
WPAI values are expressed as a percentage, where higher values indicate greater 
limitation and loss of productivity (Reilly et al., 2004, Reilly-Associates, 2019). 
 
2.2.4. The role of Health Technology Assessment 
 
In Hungary, several legal acts provide for aspects to be taken into account in 
healthcare: the role of efficiency, economy and cost-effectiveness (1993. évi 
költségvetéséről szóló törvény, 1992. évi LXXXIV. törvény, 1997. évi LXXXIII. 
törvény) (Kobelt et al., 2017). Health Technology Assessment (HTA) regulation 
in Hungary dates back to 2002, when the first professional directive on health 
technology assessment was published in Hungary, this directive was first updated 
in 2013 (Kobelt et al., 2017). 
The Hungarian HTA guideline, the „Emberi Erőforrások Minisztériuma szakmai 
irányelve az egészségügyi technológia értékelés módszertanáról és ennek 
keretében költséghatékonysági elemzések készítéséről” (2017. EüK. 3. szám 
közlemény) covers the most important chapters: the need to present the given 
technology, the description of the curative-preventive technologies to be 
compared, the choice of perspective, the type of health economic analysis, the 
measurement of health benefits related to the applied procedures, cost calculation, 
time horizon of analysis, discounting and detailed presentation of results, Budget 
Impact Analysis and other aspects (Kobelt et al., 2017).  
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The main goal is to prepare funding decisions and assess the costs and benefits of 
a given health technology (prevention, screening, diagnosis, therapy) when 
including new therapies in the social security system. In Hungary, too, legislation 
requires the need to continue cost-effectiveness and budget-impact studies prior 
to making health policy and funding decisions (EMMI Decree 7/2016 (III. 30.)). 
 
The European Network for Health Technology Assessment (EUnetHTA) defines 
health technology assessment as "summarizing available medical, social, 
economic and ethical information on the use of health technologies in a 
transparent, impartial and robust manner". Its main objective is to support “the 
most valuable, patient-centered, safe and effective health interventions possible” 
(EUnetHTA, 2007). The HTA modules recommended by EUHTA can be divided 
into the following (EUnetHTA): relative efficacy analysis (current application of 
the technology, technical characteristics, safety, clinical efficacy) and local 
evaluation (cost and economic evaluation, ethical evaluation, organizational 
impacts, patient-level and social effects, legal effects) (EUnetHTA, 2007). 
Health economics assessment most often includes the following analyses: cost-
benefit analysis and budget impact analysis. In these analyses, the given new 
technology is compared with a technology that is already generally accepted and 
used. Cost-Utility Analysis (CUA) contrasts health outcomes measured in Quality 
Adjusted Life Years (QALYs) with costs. Budget Impact Analysis (BIA) focuses 
on the financial implications of introducing a particular new technology (Gulácsi 
et al., 2012). 
 
2.2.5. Hungarian cost library 
 
There are ‘cost-libraries’ in four countries in Europe: the UK, the Netherlands, 
Germany and Austria. Partially, such data are available at regional, autonomous 
provincial level in Spain, Italy, and Sweden. 
Among the countries in our region, Austria has its own ‘cost-library’. The purpose 
of the ‘cost-library’, developed and managed by the Department of Health 
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Economics, Center for Public Health, Medical University of Vienna, is to 
communicate available unit costs as well as its various sources of unit costs. 
The creation of the Hungarian online health care cost catalogue began in 2016, 
when the Department of Health Economics of the Corvinus University of 
Budapest received support for the organization of an international conference, 
thus actually starting the process of designing the Hungarian cost library. 
During the creation of the Hungarian cost library in Hungary, the Austrian 
example was considered. Our decision was motivated by the fact that the Austrian 
'cost-library' followed a pragmatic methodology, in which a university 
department of a very similar size to our own, with its similar human resources 
could achieve a very significant result in a few years. It was also an important 
aspect that during the joint work with the Austrian department we had the 





















3.1. Health-related quality of life 
 
A Comparison of European Polish, Slovenian and British EQ-5D-3L value sets 
using a Hungarian sample of 18 chronic diseases 
Hypothesis 1. 
We assume that the European, Polish, Slovenian and UK EQ-5D-3L value sets do 
not differ significantly 
 
1.1. We assume that applying different value sets in the 18 chronic diseases that 
we examined, the health policy and funding decisions based on the results do not 
differ significantly in different countries. 
 
A detailed analysis of ’not relevant’ responses on the DLQI in psoriasis: potential 
biases in treatment decisions 
Hypothesis 2. 
We assume that the ’not relevant’ answers of the DLQI questionnaire differ in the 
different demographic groups.  
 
2.1. We assume that the effect of the differences on medical decision-making and 







The health state and productivity of the Hungarian general population 
Hypothesis 3. 
We assume that the health status and work productivity of the Hungarian general 
population can be adequately measured by the standard questionnaires we used. 
 
Characteristics and determinants of informal care in chronic diseases in 
Hungary: A comparative analysis 
Hypothesis 4. 
We assume that the characteristics and determinants of informal care in Hungary 




Cost of informal care in chronic diseases in Hungary: A comparative analysis 
Hypothesis 5. 
We assume that the social burden and cost of informal care is very significant in 
Hungary as well, in accordance with international experience. 
 
Cost-of-illness studies in nine Central and Eastern European countries 
Hypothesis 6. 
We assume that the costs of illness in Hungary are similar to those in other Central 
and Eastern European countries. 
 
6.1. We assume that in Hungary the cost data published in other Central Eastern 
European country can be utilized and transferred better than the cost data 





Hungarian cost library 
Hypothesis 7. 
We assume that a Hungarian cost library can be created as sufficient local data is 
available. 
 
7.1. We assume that the Hungarian cost library can contribute to the development 
of appropriate and sustainable health care financing decisions. 
 
7.2. We assume that the Hungarian unit costs and cost are significantly different 







4.1. Health-related quality of life 
4.1.1. A Comparison of European Polish, Slovenian and British EQ-5D-3L 
value sets using a Hungarian sample of 18 chronic diseases 
  
 
We aimed to compare the Slovenian, Polish, British and European EQ-5D-3L 
value sets, which are most commonly used or are potentially applicable for health 
economic evaluations in the CEE region. Our study was based on the comparative 
analysis of patient level data from cross-sectional surveys conducted in Hungary 
among patient populations in 18 different chronic conditions. We explored the 
differences of the EQ-5D-3L index scores calculated with the four value sets by 
diagnosis, age group and disease severity. Furthermore, we analysed the potential 
impact of the choice of value sets on health priority setting by comparing the 
disease burden evaluations across different conditions using different value sets. 
 
4.1.2. A detailed analysis of ’not relevant’ responses on the DLQI in 
psoriasis: potential biases in treatment decisions 
 
Our objective was to explore the occurrence of NRRs on the DLQI on a large 
sample of psoriasis patients and to examine the effect of several socio-
demographic and clinical factors on giving NRRs. 
 
4.1.3. The health state and productivity of the Hungarian general 
population 
 
We aimed to assess the health state, well-being and productivity loss experienced 
by the Hungarian general population with questionnaires like the ICECAP, WPAI 
and EQ-5D-5L, which are suitable for evaluating outcomes and contributing to 
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the evaluation of strategy-making in a number of sectors (health-social sector, 
labour market).  
 
4.1.4. Characteristics and determinants of informal care in chronic 
diseases in Hungary: A comparative analysis 
 
The aim of our research was to analyse the characteristics and determinants of 
informal car in chronic conditions, with a special attention to observing the 
relationship between patients’ health-related quality of life (measured by the EQ-





4.2.1. Cost of informal care in chronic diseases in Hungary: A comparative 
analysis  
 
Our aim was to analyse the cost of informal care in chronic disease. We performed 
a comparative analysis in 13 different chronic diseases. We analysis previous 
studies where patient level data was available. 
 
4.2.2. Cost-of-illness studies in nine Central and Eastern European countries 
 
This review has been undertaken to provide a description of the COI studies in 
nine CEE countries, namely Austria, Bulgaria, the Czech Republic, Croatia, 
Hungary, Poland, Romania, Slovakia, Slovenia, in the past ten years. The main 






4.2.3. Hungarian cost library 
 
Our aim was to create a Hungarian cost library, containing country specific cost 
data. We aimed to analyse the possibilities of using the database for providing 







5.1. Health-related quality of life 
 
5.1.1. A Comparison of European Polish, Slovenian and British EQ-5D-3L 
value sets using a Hungarian sample of 18 chronic diseases 
 
5.1.1.1. EQ-5D-3L value sets 
 
The EQ-5D-3L value set has been developed in several countries. However, in 
the Central and Eastern European region, only Poland and Slovenia have their 
own set of country-specific values. In the countries of the region, the United 
Kingdom (hereafter UK) utility value set was often used for evaluation (Devlin et 
al., 2017), for example, in Hungary it was also used in population surveys (Baji 
et al., 2015, EuroQolGroup, Dolan, 1997, Rencz et al., 2016). The European value 
set was developed for international use, with the involvement of 6 countries, 
however, its application is currently not widespread in the countries of the region 
(Greiner et al., 2003, Rencz et al., 2016). In the present study, we compared four 





This current study is a secondary analysis of 18 previous surveys conducted by 
the Department of Health Economics of the Corvinus University of Budapest. We 
only included those patients in our analysis, who had answers in all five EQ-5D-
3L dimensions; hence EQ-5D-3L index scores could be calculated using the four 




5.1.1.3. Statistical analysis  
 
We applied descriptive methods and graphical representation of key findings. As 
sample sizes varied substantially across the datasets (min: N=61, max: N=249), 
analytical weights were constructed to make the pooled dataset a balanced sample 
of the 18 diseases. The sum of weights was set to 100 by each condition. We 
calculated weighted mean and percentage values when reporting characteristics 
of the pooled sample totals. We compared the four value sets by 1) EQ-5D-3L 
dimensions, 2) by diagnosis, 3) by respondents’ subjective health assessment (EQ 
VAS) and 4) by age group, according to the following. 1) When comparing value 
sets by EQ-5D-3L dimensions, we graphically represented indices of health states 
with moderate and severe levels of isolated problems in each dimension (e.g. 
21111, 31111 etc.), as well as the combinations of moderate and severe problems 
(21122, 22222, 32233, 33333) against full health (11111). This comparison 
allows us to take into account the full disutility arising from the severity of 
problems and the dimension-specific preferences. Although the distribution of 
index values was not normal, the sample size was sufficiently large to allow the 
comparison of diagnosis subgroups using two-sided paired t-tests. Finally, for 
each value set, we calculated a so-called disease burden (DB) value and its 
sensitivity to the choice of value set. 
 
5.1.2. A detailed analysis of ’not relevant’ responses on the DLQI in 
psoriasis: potential biases in treatment decisions 
 
5.1.2.1. Questionnaire survey 
 
We performed two cross-sectional questionnaire surveys in Hungary, in two 
clinics, among patients suffering from psoriasis. The first study was conducted 
between 2012 and 2013, involving 200 patients, and the second questionnaire 
survey was conducted between 2015 and 2016, involving 238 patients with 
psoriasis in different disease severity. The responses of patients included in both 
questionnaire surveys were considered only once, and patients whose DLQI 
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scores could not be calculated due to missing data were excluded, so a total of 
428 patients were included in our sample. 
 
5.1.2.2. Outcome measures 
 
To assess the health-related quality of life of the patients, we used the EQ-5D-3L 
questionnaire. The EQ-5D-3L questionnaire was used to assess the general health 
of the patients. The DLQI questionnaire was used to measure disease-specific 
quality of life. To assess the severity of the disease, the so-called The “Psoriasis 
Area Severity Index” (PASI) score was used, which can range from 0 to 72, is 
used, with higher values indicating higher disease severity. 
 
5.1.2.3. Statistical analysis 
 
Descriptive statistics were performed for our whole sample. Subgroups were 
formed based on DLQI scores. Two methods were used to evaluate ‘not relevant’ 
DLQI responses: the frequency of ‘not relevant’ DLQI responses was determined, 
and the number of ‘not relevant’ DLQI responses per patient (which ranged from 
0 to 8) was determined. 
Due to the non-normal distribution of our data, we used non-parametric tests. To 
explore the determinants of irrelevant responses, we constructed a multivariate 
logistic regression model. The relationship between gender and irrelevant 
responses was examined using a chi-square test. The analyses were performed 









5.1.3. The health state and productivity of the Hungarian general 
population 
 
5.1.3.1. Questionnaire survey 
 
We conducted a cross - sectional questionnaire survey in May - June 2019 on a 
sample representative of the most important demographic characteristics of the 
Hungarian population. Ethical approval for the questionnaire was granted by the 
Scientific and Research Ethics Committee (approval number: 10058-3 / 2019 / 
EKU). Participants gave their consent to participate in the study. 
The questionnaire survey was part of a larger population-based survey (Baji et al., 
2019, Péntek et al., 2020). In order to assess the health status and working 
capacity of the Hungarian population, we focused on the following sections: 
•Socio-demographic characteristics: age, gender, education, marital status 
•Employment situation 
•Characteristics of the respondent's household (household size, net monthly 
income, type and place of residence) 
•Health status of the respondent 
•Productivity of the respondent  
 
5.1.3.2. Outcome measures 
 
To measure labour productivity loss, the WPAI-GH questionnaire presented 
earlier in the dissertation, the EQ-5D questionnaire to assess the health status of 
participants, the MEHM (Minimum European Health Module) and ICECAP-A 
(respondents under 65) and ICECAP-O (Respondents older than 65 years) were 




5.1.3.3. Statistical analysis 
 
A database was constructed from the data from the questionnaires in IBM SPSS 
Statistics 25 (IBM SPSS, Version 25.0. Armonk, NY: IBM Corp., 2012). 
Descriptive statistics were performed to characterize participants ’labour 
productivity, health status, and well-being. To measure the loss of labour 
productivity measured by the WPAI questionnaire, a subgroup analysis was 
performed. Non-parametric tests (Kruskal-Wallis and Mann-Whitney U tests) 
were used to test the significance of the differences. To explore correlations 
between different measures, we calculated pairwise Spearman rank correlations 
due to the non-normal distribution of our variables. 
 
5.1.4. Characteristics and determinants of informal care in chronic 
diseases in Hungary: A comparative analysis 
 
5.1.4.1. Surveys included in our analysis 
 
We reviewed the questionnaire research conducted by the Department of Health 
Economics of the Corvinus University of Budapest in recent years. The studies 
were selected where informal care in chronic diseases among Hungarian patients 
was measured in the framework of a cross-sectional survey, the so-called EQ-5D 
questionnaires’ 3L version (see above) was also completed and (anonymized) 
patient-level data were available. 
 
5.1.4.2. Measuring informal care 
 
To assess the informal care use, a series of questions compiled by the Department 
were used in the studies, except in the case of dementia, which is therefore 
discussed separately. Informal care was assessed uniformly for the past week, and 
in each case, the patients themselves answered the questions. In most studies, 
patients had to report the number of hours they had taken in the past week, with 
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the exception of epilepsy, benign prostatic hyperplasia (BPH) and osteoporosis, 
where the number of occasion and the number of hours/occasion were assessed. 
For bladder cancer (BC), the answers to the questions on weekly informal care 
and the number of hours per occasion were incomplete, so this variable was not 
included in the analyses of informal care hours. 
The dementia survey was conducted as part of an international study and used to 
measure the use of formal and informal resources using a special standard 
questionnaire developed specifically for the dementia survey, which also included 
questions on informal care (Érsek et al., 2010). The Resource Utilization in 
Dementia (RUD) is a standard questionnaire that is suitable for comparing 
resource use and costs for dementia in different countries. The questionnaire was 
widely used, the Hungarian version of RUD was used in the research 
(EuroQolGroup, 1990). In our analysis, we compared the one-month informal 
care periods from the RUD questionnaire to the number of hours per week. 
The time of assistance received from another person was normally maximized at 
24 hours per day (i.e., 168 hours per week) per patient. While we ruled out cases 
where the patient admitted to being treated for more than 24 hours, which is 
actually possible if more caregivers help and supervise the patient, we wanted to 
avoid overestimating informal care. Secondary analysis was performed using a 
more conservative approach, maximizing the number of hours of informal care 
per patient at 8 per day (i.e., 56 hours per week). 
 
5.1.4.3. Health state measure by the EQ-5D questionnaire 
 
The validated Hungarian version of EQ-5D-3L was used in the selected studies, 




Patient-level data were collected from the original databases in a standard manner 
and recorded in IBM SPSS Statistics (IBM SPSS, Version 21.0. Armonk, NY: 
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IBM Corp., 2012). We recorded the type of disease, the age of the patients, the 
sex of the patients, their educational attainment, their housing situation, the time 
since the diagnosis, the five dimensions of EQ-5D-3L and the health status of EQ 
as measured by VAS, and the informal care weekly hours. 
 
5.1.4.5. Statistical analysis 
 
We performed descriptive statistics to describe the demographic attribute, 
informal care use and health-related quality of life of the patients. We performed 
sub-group analysis by diagnosis and informal care use. Due to the non-normal 
distribution of our data, we used non-parametric tests. To analyse the relationship 
between the EQ-5D, EQ VAS and the informal care time, we used Spearman’s 
rank correlations. To explore the determinants of informal care time, we built a 









The detailed methodology has been published previously (Beretzky et al., 2017). 
We reviewed those questionnaire surveys conducted by the Department of Health 
Economics of the Corvinus University of Budapest in recent years, that covered 
the survey of informal care and used the previously presented EQ-5D-3L 
questionnaire suitable for measuring health status. The research used a series of 
questionnaires compiled by the department and completed by patients to measure 
informal care for the week prior to completion. A secondary analysis of the results 
of a total of 13 studies was performed in the following disease areas: psoriatic 
arthritis (AP) (Brodszky et al., 2009), age-related macular degeneration (AMD) 
(Brodszky et al., 2014a), dementia (Érsek et al., 2010), endometriosis (Simoens 
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et al., 2012), epilepsy (Pentek et al., 2013), benign prostatic hyperplasia (BPH) 
(Rencz et al., 2015c), osteoporosis (Péntek et al., 2016b), Parkinson’s disease 
(Tamás et al., 2014), psoriasis (Balogh et al., 2014, Rencz et al., 2014), 
rheumatoid arthritis (RA) (Péntek et al., 2007), systemic sclerosis (SSc) (Minier 
et al., 2010), multiple sclerosis (SM) (Péntek et al., 2012b) and schizophrenia 
(Péntek et al., 2012c).  
5.2.1.2. Health-related quality of life 
 
To measure the health-related quality of life, we used the Hungarian version of 
the EQ-5D-3L questionnaire. We wanted to pay special attention to patients in the 
worst health states. In order to do this, we selected those who has and EQ-5D-3L 
index score 0 or lower.  
5.2.1.3. Informal care 
 
To avoid overestimating the informal care use, we maximized the informal care 
hours in 24 hours daily (168 hours weekly). In our secondary analysis, we used a 
more conservative approach, where we maximized the informal care hours in 8 
hours/day. To calculate the cost of informal care we multiplied the number of 
hours of informal care with the average net hourly wage, which was  973 HUF in 
2017 (KSH, 2017). 
 




5.2.2.1. Selection of the publications 
 
We conducted a literature search in the Medline, EMBASE, The Cochrane 
Library, CINAHL, and Web of Science databases to identify publications 
containing the cost of illness data. The search strategy consisted of a combination 
of the search term “cost of illness” and the term “Hungary”. 
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Our search reviewed publications in English and Hungarian published between 
January 1, 2006 and June 30, 2017. 
After the search, we examined the results by title and abstract, and then in the 
second round, we examined the full text and decided on their selection. Reports 
published exclusively in the abstract and review were excluded.  
Publications were selected based on the following criteria: 1. contained cost of 
illness data for a specific disease, 2. the publication was an original publication, 
3. the publication was fully available, 4. the patient population in the publication 
originated from Austria, Bulgaria, the Czech Republic, Croatia, Hungary 




We summarized the most important data of the selected publications (year of 
publication, place, language and financial support status) in a summary table, 
created in Microsoft Excel. In addition, the perspective used in the publication, 
the name of the diagnosis / intervention in the publication and the cost data 
included in the selected publications were also identified and recorded 
5.2.3. Hungarian cost library 
The literature search was conducted in four steps, with the search for cost of 
illness publications, cost-effectiveness, budget-impact analysis publications, and 
in the case of Hungarian, Hungarian language literature, we performed a manual 
search. When we refreshed our search, we performed a free word search for the 
term “cost”. 
The search was conducted as follows: 
1. search for cost of illness publications, time period: January 1, 2006 - June 
30, 2017 
2. cost-effectiveness, budget-impact analysis search for publications, time 
period: 1 January 2006 - 30 June 2017 
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3. manual search in Hungarian literature in Hungarian, time period: January 
1, 2006 - March 21, 2020 
4. update of our search to identify the latest publications. period: 1 July 2017 
- 21 March 2020 
 
5.2.3.1. Cost of illness studies 
We conducted a literature search in the Medline, EMBASE, The Cochrane 
Library, CINAHL, and Web of Science databases to identify publications 
containing the cost of a disease. The search strategy consisted of a combination 
of the search term “cost of illness” and the term “Hungary”. 
Our search reviewed publications in English and Hungarian published between 
January 1, 2006 and June 30, 2017. 
After the search, we examined the results by title and abstract, and then in the 
second round, we examined their full text and decided on their selection. Reports 
published exclusively in the abstract and review were excluded. 
We applied the following criteria, to identify the publications: 
1. included cost of illness data for a specific disease, 
2. were original communications, were fully available, 
3. the patient population included in the study was selected in Hungary. 
 
5.2.3.2. Cost-effectiveness, budget-impact analysis  
 
In order to identify cost-effectiveness, budget-impact analysis analyses, we 
searched the OVID MEDLINE database. Our search reviewed publications in 
English and Hungarian published between January 1, 2006 and June 30, 2017. 
After the search, we examined the results by title and abstract, and then in the 
second round, we examined their full text and decided on their selection. 
Reports published exclusively in the abstract and review were excluded.  
 




1. included cost-effectiveness, budget impact analysis or cost of illness 
analysis, or any unit cost data 
2. were original, fully available publication, 
3. the patient population included in the study was selected in Hungary. 
 
 
5.2.3.3. Manual search in the Hungarian literature 
 
In order to identify non-indexed, local literature, we conducted a manual search 
of the searchable database of the contents of Hungarian-language journals 
(MATARKA, https://matarka.hu/), which lists the contents of scientific and 
professional journals published in Hungary in a searchable form. After reviewing 
the relevant results, the original announcements containing data on some disease 
cost and cost-effectiveness were selected. 
Our literature review also included a review of relevant technology analysis 
reports. Technology analysis reports prepared by the Department of Health 
Economics (and its predecessors) of the Corvinus University of Budapest, which 
have an ISBN number, are publicly available and provide domestic cost data for 
a specific disease / therapy, have been selected. No technology analysis report 
discussing any specific diagnosis or intervention is available on the website of the 
National Health Insurance Fund and its successors (National Health Insurance 
Fund Manager) (http://www.neak.gov.hu/felso_menu/szakmai_oldalak). The 
archive of the formerly operating Strategic Health Research Institute (ESKI) is no 
longer available on the website of the Ministry of National Resources 
(https://www.kormany.hu/hu/emberi-eroforrasokminiszteriuma/egeszsegugyert-
felelos-allamtitkarsag). The currently available publications of the current State 
Center for Health Care (ÁEEK; before March 1, 2015: Institute of Pharmaceutical 
and Health Quality and Organizational Development) (ERA-Health Systems 
Database) did not include a technology analysis report on a specific diagnosis or 




5.2.3.4.Update of the search 
 
To identify publications published between July 1, 2017, and March 21, 2020, we 
conducted a free-text search using the “cost” search term in the PubMed Medline 
database. The term “Hungary” was also marked in the search and the search 
period to be searched was marked. The results were reviewed and sorted as 
follows: In this case, the articles published only in the abstract form and the 
review articles were excluded. After that, the results were examined by title and 
abstract, and in the second round, after examining their full text, we decided on 
their selection, according to the following criteria: 
1. included cost data for a disease or intervention, or non-disease-specific health 
costs 
2. original communications and were fully available, 
3. the patient population included in the publication was selected in Hungary. 
 
When updating the search, in order not to lose results, we continued the “cost” 
free-text search strategy, which resulted in a number of irrelevant or non-health 
economics publications appearing in our results, which were excluded. 
 
5.2.3.5. Hungarian cost library 
 
The most important data of the selected publications (year of publication, year of 
cost calculation, perspective used in the publication, name of the diagnosis / 
intervention in the publication) and the cost data in them were summarized in a 
summary table in Microsoft Excel. 
Costs were categorized by textbook breakdown (Gulácsi et al., 2012): direct 
health costs, direct non-health costs, and indirect costs. Within the main cost 
categories, costs were classified according to whether we could separate costs 
incurred in outpatient or inpatient care. 
The Hungarian cost library also includes the costs of products and services not 
financed by social security, which have been treated separately. In the case of the 
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costs included in the publications, we wanted to identify in each case what sources 
the authors used to calculate the given cost. If disclosed in a particular publication, 
the unit costs used to calculate the costs have also been considered and 
recognized. The cost data identified in the publications were also classified 







6.1. Health-related quality of life 
6.1.1. A Comparison of European Polish, Slovenian and British EQ-5D-3L 




The 18 chronic diseases belonged to 9 different ICD-10 groups. Our total sample 
included 2421 patients with psoriatic arthritis (PsA) (Brodszky et al., 2009), age-
related macular degeneration (AMD)  (Brodszky et al., 2010d), attention deficit 
hyperactivity disorder (ADHD) (Pulay et al., 2016), dementia (Érsek et al., 2010), 
diabetes (DM) (Brodszky et al., 2010d), endometriosis (ENDO) (Simoens et al., 
2012), epilepsy (Pentek et al., 2013), bladder cancer (BC) (Hever et al., 2015), 
benign prostatic hyperplasia (BPH) (Rencz et al., 2015a), osteoporosis (OP) 
(Rencz et al., 2016), peripheral arterial occlusive disease (PAOD) (Balogh et al., 
2013), Parkinson’s disease (PD) (Tamás et al., 2014), psoriasis (PSO) (Rencz et 
al., 2014, Balogh et al., 2014), rheumatoid arthritis (RA) (Péntek et al., 2007), 
overactive bladder (OAB) (Péntek et al., 2012a), systemic sclerosis (SSc) (Minier 
et al., 2010), multiple sclerosis (MS) (Péntek et al., 2012b) and schizophrenia 
(SCZ) (Péntek et al., 2012c). (Table 1.) 
The mean age of the patients was 55.87 (SD = 17.75) years. More than half of the 
patients were older than 70 years with dementia, age-related macular 
degeneration, benign prostatic hyperplasia, and peripheral arterial vascular 
disease. More than half of the patients were women (n = 1356, 58.6%) and it is 
important to mention that in some diseases only female patients were included in 
our sample (endometriosis, osteoporosis, hyperactive bladder syndrome) even in 
benign prostatic hyperplasia only men. The mean disease duration in our sample 
was 8.75 (SD = 8.95) years, with a distinctly high mean disease duration for 
psoriasis and epilepsy. (Table 1.) 
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Table 1. Demographic characteristics of the sample 
 
 Diagnosis Number of patients (n) Disease duration (year) Age mean (SD) Female n (%) 
Psoriatic arthritis 177 9.30 (9.24) 49.89 (12.76) 101 (57.1%) 
Psoriasis 192 21.66 (11.77) 50.49 (12.79) 61 (31.8%) 
Peripheral arterial occlusive disease 103 NA 70.00 (10.21) 45 (43.7%) 
Age-related macular degeneration 122 2.94 (2.54) 75.16 (7.88) 76 (62.3%) 
Rheumatoid arthritis 249 9.15 (9.33) 55.38 (12.32) 214 (86.3%) 
Systemic sclerosis 80 7.16 (6.63) 57.39 (9.60) 72 (90.0%) 
Dementia 86 NA 77.61 (8.60) 51 (60.0%) 
Diabetes 264 NA 61.31 (10.98) 151 (57.2%) 
Endometriosis 79 7.68 (6.33) 32.67 (4.80) 79 (100%) 
Osteoporosis 207 7.49 (5.60) 69.57 (8.93) 207 (100%) 
Attention deficit hyperactivity disorder 75 NA 30.44 (10.49) 17 (22.7%) 
Bladder cancer 148 3.56 (3.78) 66.24 (9.61) 50 (33.8%) 
Benign prostatic hyperplasia 237 5.53 (4.79) 70.38 (8.18) 0 (0.0%) 
Epilepsy 96 15.38 (11.55) 36.16 (12.12) 56 (58.3%) 
Overactive bladder 61 NA 57.72 (11.56) 61 (100.0%) 
Parkinson’s disease 99 8.08 (5.59) 62.67 (11.32) 31 (33.0%) 
Schizophrenia 78 NA 44.24 (13.05) 36 (46.2%) 
Multiple sclerosis 68 7.02 (5.90) 37.96 (9.08) 48 (70.6%) 




6.1.1.2. Problems reported in the EQ-5D-3L dimensions 
 
In our sample, 519 patients (20.7%) did not report a problem in any of the EQ-
5D-3L dimensions, and another 420 patients (16.1%) reported a problem (at any 
level) in all five dimensions. 419 patients (17.6%) reported severe problems in at 
least one dimension, and even 2002 patients (82.4%) did not report severe 
problems in any dimension. 
 
The distribution of patients according to the reported problem is shown in Figure 
2. The most common problem was in patients with dementia (96.5%), rheumatoid 
arthritis (95.2%), peripheral arterial disease (95.2%) and psoriatic arthritis 
(94.4%), and most rarely in endometriosis (44.3%). epilepsy (52.1%) and benign 
prostatic hyperplasia (53.2%). 
 
Considering our entire sample, the least affected dimension was Self-care, in 
which 20.5% and 2.6% of patients reported a moderate and severe problem. Most 
problems were reported by patients in the Pain / discomfort and Anxiety / 
depression dimensions: moderate problems in 51.7% and 46.5%, severe problems 
in 10.3% and 9.0%, respectively. 
 
Proportion of those with any level of problem in the dimensions Mobility, Self-
sufficiency, Usual activities, Pain / discomfort and Anxiety / depression in the 
highest peripheral arterial disease (89.3%), rheumatoid arthritis (56.2%), 
rheumatoid arthritis (20.9%), rheumatoid arthritis (8.4%) and schizophrenia 
(76.9%). (Figure 2) 
 
Patients with dementia reported severe problems in most cases in the dimensions 
of Mobility (11.3%), Self-care (19.7%), Usual activities (36.1%) and Anxiety / 
depression (30.2%), even in the peripheral patients with arterial disease reported 





Figure 2. Problems reported in the five EQ-5D-3L dimensions by diagnosis 
 
 
ADHD: attention deficit hyperactivity disorder; AMD: age-related macular degeneration; BC: 
bladder cancer; BPH: benign prostatic hyperplasia; DM: diabetes mellitus, ENDO: endometriosis; 
MS: multiple sclerosis; OAB: overactive bladder; OP: osteoporosis; PAOD: peripheral arterial 
occlusive disease; PsA: psoriatic arthritis; PSO: psoriasis; RA: rheumatoid arthritis; SCZ: 
schizophrenia; SSc: systemic sclerosis 
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6.1.1.3. Comparison of EQ-5D-3L value sets 
 
Comparison of EQ-5D-3L index values by dimensions 
Figure 3 shows the relative significance of the EQ-5D-3L dimensions in the four 
value sets. With the exception of the severe problem reported in the Usual 
Activities and Pain / Discomfort dimensions, the Polish value set gave the highest 
value for moderate or severe problems reported in all dimensions. In the case of 
moderate problems, in the case of Slovenia, even in the case of severe problems, 
the UK value set was the lowest. 
 
The loss of utility relative to total health due to the existence of moderate 
problems was relatively lower for the Polish and UK value sets, but a larger 
decrease was observed in the presence of severe problems. In the case of the 
Slovenian value set, the decrease in utility due to moderate problems is 
accompanied by a larger decrease due to more severe problems. The differences 
between overall health and moderate problems, as well as measured and severe 
problems, were similar for the European value set. 
 
In the presence of the most severe problems (‘33333’), the UK and Polish value 
sets provided the lowest values. Of all the possible (243) EQ-5D-3L profiles, the 
incidence of conditions with a negative utility value (“worse than death”) was the 
most common in the UK value set (35%), followed by Poland (3%), Slovenia 
(9%) and European (2%) values set followed. 
 
For severe problems, the Polish and UK value sets showed the largest decreases 
in utility in the Pain / discomfort dimension. In contrast, a serious problem in the 
Mobility dimension had the greatest negative impact on the EQ-5D-3L index for 
the use of the Slovenian and European value sets. Based on our results, we 
expected that both the severity and the location of the reported problem would 
affect the differences in utility values calculated with the four different value sets. 





Figure 3.  EQ-5D-3L index scores for selected health states by the four 
different value sets 
 
 
Comparison of value sets by diagnosis 
 
For our analysis by diagnosis, we calculated the EQ-5D-3L index values  (mean, 
standard deviation) with all four sets of values in each diagnosis. The weighted 
average of the EQ-5D-3L index values in our total sample was 0.598 (SD = 
0.279), 0.661 (SD = 0.257), 0.770 (SD = 0.261) and 0.644 (SD = 0.334) in 
Slovenia, Europe, Poland and the UK value sets, respectively. All pairwise value 





Table 2. EQ-5D-3L index scores by diagnosis 
 
Diagnosis EQ-5D-3L index mean (SD) Two-sided paired t-test p-values 












Rheumatoid arthritis 0.411 (0.217) 0.506 (0.235) 0.464 (0.334) 0.646 (0.270) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Psoriatic arthritis 0.423 (0.230) 0.513 (0.244) 0.467 (0.347) 0.645 (0.288) <0.001 <0.001 0.002 <0.001 <0.001 <0.001 
Systemic sclerosis 0.486 (0.240) 0.583 (0.218) 0.580 (0.285) 0.736 (0.234) <0.001 <0.001 <0.001 <0.001 <0.001 0.770 
Osteoporosis 0.519 (0.242) 0.603 (0.233) 0.580 (0.319) 0.729 (0.258) <0.001 <0.001 <0.001 <0.001 <0.001 0.002 
Epilepsy 0.804 (0.229) 0.826 (0.210) 0.831 (0.244) 0.900 (0.166) 0.001 <0.001 0.006 <0.001 <0.001 0.384 
Multiple sclerosis 0.586 (0.252) 0.670 (0.222) 0.669 (0.278) 0.795 (0.195) <0.001 <0.001 <0.001 <0.001 <0.001 0.870 
Parkinson’ disease 0.476 (0.240) 0.583 (0.226) 0.588 (0.281) 0.741 (0.202) <0.001 <0.001 <0.001 <0.001 <0.001 0.523 
Dementia 0.381 (0.288) 0.424 (0.286) 0.333 (0.430) 0.523 (0.405) <0.001 <0.001 0.023 <0.001 <0.001 <0.001 
Attention deficit hyperactivity disorder 0.697 (0.188) 0.727 (0.175) 0.735 (0.222) 0.846 (0.142) <0.001 <0.001 0.005 <0.001 <0.001 0.320 
Schizophrenia 0.626 (0.214) 0.658 (0.212) 0.644 (0.295) 0.778 (0.227) 0.002 <0.001 0.320 <0.001 <0.001 0.261 
Endometriosis 0.880 (0.146) 0.888 (0.136) 0.902 (0.124) 0.950 (0.066) 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Benign prostatic hyperplasia 0.792 (0.228) 0.838 (0.181) 0.852 (0.187) 0.913 (0.114) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Overactive bladder 0.611 (0.256) 0.678 (0.227) 0.668 (0.314) 0.787 (0.253) <0.001 <0.001 0.005 <0.001 <0.001 0.489 
Psoriasis 0.647 (0.271) 0.706 (0.246) 0.694 (0.310) 0.808 (0.226) <0.001 <0.001 <0.001 <0.001 <0.001 0.056 
Bladder cancer 0.729 (0.236) 0.775 (0.205) 0.784 (0.242) 0.874 (0.152) <0.001 <0.001 <0.001 <0.001 <0.001 0.051 
Diabetes 0.665 (0.276) 0.728 (0.243) 0.723 (0.295) 0.826 (0.220) <0.001 <0.001 <0.001 <0.001 <0.001 0.350 
Peripheral arterial disease 0.413 (0.252) 0.508 (0.274) 0.426 (0.411) 0.589 (0.359) <0.001 <0.001 0.527 <0.001 <0.001 <0.001 
Age-related macular degeneration 0.622 (0.262) 0.679 (0.250) 0.657 (0.334) 0.780 (0.246) <0.001 <0.001 0.013 <0.001 <0.001 0.020 
Total* 0.598 (0.279) 0.661 (0.257) 0.644 (0.334) 0.770 (0.261) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
EU: European; PL: Polish; SI: Slovenian; UK:United Kingdom’s value set 





Patients with endometriosis had the highest, and patients suffering from dementia had the 
lowest mean EQ-5D-3L index value in all four value sets. The largest difference between 
two value sets was found in the diagnosis of Parkinson's disease between the index values 
calculated with the Slovenian and Polish value sets (0.265). The comparison of the four 
value sets with pairwise t-test showed significant differences in most diagnoses. In 
schizophrenia, the UK value set did not differ significantly from the Slovenian and 
European value sets. In the other diagnoses, 5 or 6 pairwise comparisons showed 
significant differences. The UK and European values did not differ significantly in 10 
diagnoses, and the UK and Slovenia in 2 of the 18 diagnoses. All other comparisons 
showed significant differences in all diagnoses. 
 
Comparison of value sets according to the assessment of patients' subjective health status 
We examined how disease severity affected differences between value sets. Subjective 
assessment by EQ VAS was used to express disease severity. We were able to identify 
three well-distinguishable EQ VAS “areas” according to patterns of value set differences. 
(Figure 4.) The index values calculated with the Polish set of values were the highest in 
the entire EQ VAS range. The largest difference (between four sets of values) was found 
in the EQ VAS range between 40 and 80 (n = 437, 61.7%). In this range, the Slovenian 
index values were the lowest, even the European and UK gave almost the same index 
score. The smallest differences were found in the range of EQ VAS between 80 and 100 
(n = 437, 20.4%), and the value sets showed a difference in the range of EQ VAS below 
40 (n = 437, 17.9%), where the Slovenian and Polish stocks converged, while the UK 









Figure 4. Comparison of value sets by patients’ subjective health assessment 
 
 
Comparison of value sets in different age groups 
 
We also wanted to analyse how the differences in EQ-5D-3L index values calculated with 
the four different sets of values were influenced by the patient's age. Three age groups 
were distinguished: those aged 18-34, 35-54, and 55 years. Of the 2421 patients, 16.3% 
belonged to the youngest (n = 275), 26.7% to the middle (n = 609), and 56.6% (n = 1525) 
to the oldest age group. 
  
More than half of the patients were in the youngest age group for attention deficit 
hyperactivity disorder (69.3%), endometriosis (64.6%), and epilepsy (54.2%). In some 
diseases, which typically affect the elderly population, the majority of patients were over 
55 years of age: 100% in elderly macular degeneration, 96.5% in dementia, 95.8% in 
benign prostatic hyperplasia, 95.2% in peripheral arterial vascular disease, and 93.7% in 
osteoporosis.  The Slovenian, European, Polish and UK index values were 0.765 (SD = 
0.214), 0.793 (SD = 0.190), 0.886 (SD = 0.140) and 0.804 (SD = 0.213) in the 18-34 age 
group, respectively, 0.601 (SD = 0.277), 0.662 (SD = 0.255), 0.773 (SD = 0.251) and 
0.644 (SD = 0.329) in the 35-54 age group, and 0.548 (SD = 0.277), 0.622 (SD = 0.262), 
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0.735 (SD = 0.281) and 0.598 (SD = 0.350) in the group over 55 years of age. All value 
set comparisons showed significant differences (p0.001). 
 
In each age group, the value calculated with the Slovenian value set was the lowest and 
the Polish value set the highest. The difference between the youngest and oldest age 
groups was the highest with the Slovenian value set (0.217), followed by the UK (0.206), 
European (0.171) and Polish (0.150) value sets. Comparison by all age groups showed 
significant results (p <0.001). 
 
Sensitivity of disease burden analysis to value set selection 
 
Despite the fact that the British value set based on the TTO method is most often used 
both in Hungary and in the Central and Eastern European region (Rencz et al., 2016; 
Herszényi et al., 2015), we wanted to assess the extent to which disease burden 
measurement affects the choice of value set in the 18 diagnoses examined. (Figure 5.) 
 
Positive and negative differences were also observed in some diagnoses for all four value 
sets, with differences in the Slovenian and UK value sets in particular. Values for 
dementia are 0.15 point lower, even for multiple sclerosis and Parkinson's disease 0.05 
points higher, using the Slovenian value set instead of the UK. Polish values differed from 
British values in the diagnosis of psoriatic arthritis and from European values in dementia. 
Differences in Polish and Slovenian value sets were also significant in the diagnoses of 
multiple sclerosis and Parkinson’s disease. The value sets yielded very similar index 







Figure 5. Differences of DB evaluations compared to the British TTO value set 
 
ADHD: attention deficit hyperactivity disorder; AMD: age-related macular degeneration; BC: bladder 
cancer; BPH: benign prostatic hyperplasia; DM: diabetes mellitus, ENDO: endometriosis; MS: multiple 
sclerosis; OAB: overactive bladder; OP: osteoporosis; PAOD: peripheral arterial occlusive disease; PsA: 
psoriatic arthritis; PSO: psoriasis; RA: rheumatoid arthritis; SCZ: schizophrenia; SSc: systemic sclerosis  
 
The “sensitivity index” was used to assess the sensitivity of the value sets. (Table 3) A 
total of 153 pairwise comparisons were performed in the 18 diagnoses (n = 18 * 17/2), 
and 22.9% showed mixed results. Combinations of non-significant deviations and 
significant deviations (in one direction) were the largest deviations. Mainly due to the 
low number of items in our sample, we did not find a pairwise comparison in which 
alternative sets of values would have led to a statistically significant, different ranking (+ 
DB with a given set of values, but - with another). The “sensitivity index” results suggest 
that different diseases are not equally sensitive to the different value sets. For diagnoses 
(dementia, multiple sclerosis, and peripheral arterial vascular disease) outcomes were 
highly dependent on the value set choice, however, in other diagnoses (such as benign 
prostate enlargement or bladder cancer), results were not significantly affected by the 
choice of value set. 
66 
 




Pairwise DB differences based on comparing 
All four value setsa EU vs. PLc  EU vs. SIc EU vs. UKc SI vs. PLc  SI vs. UKc  PL vs.  UKc  
Rheumatoid arthritis 17 0.118 0.059 0.000 0.059 0.118 0.118 0.000 
Psoriatic arthritis 17 0.176 0.118 0.000 0.118 0.118 0.118 0.000 
Systemic sclerosis 17 0.294 0.294 0.000 0.176 0.294 0.176 0.118 
Osteoporosis 17 0.235 0.235 0.000 0.118 0.235 0.118 0.118 
Epilepsy 17 0.118 0.059 0.000 0.000 0.059 0.118 0.059 
Multiple sclerosis 17 0.412 0.235 0.059 0.059 0.412 0.235 0.176 
Parkinson’s disease 17 0.294 0.294 0.000 0.294 0.294 0.294 0.000 
Dementia 17 0.412 0.235 0.118 0.235 0.412 0.412 0.000 
Attention deficit hyperactivity disorder 17 0.294 0.294 0.000 0.294 0.294 0.294 0.000 
Schizophrenia 17 0.294 0.294 0.000 0.118 0.235 0.059 0.176 
Endometriosis 17 0.176 0.118 0.059 0.000 0.118 0.118 0.118 
Benign prostatic hyperplasia 17 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Overactive bladder 17 0.294 0.294 0.000 0.235 0.294 0.235 0.059 
Psoriasis 17 0.294 0.235 0.118 0.235 0.235 0.235 0.000 
Bladder cancer 17 0.059 0.000 0.059 0.000 0.059 0.059 0.000 
Diabetes 17 0.118 0.059 0.000 0.000 0.118 0.059 0.059 
Peripheral arterial occlusive disease 17 0.353 0.353 0.000 0.235 0.353 0.235 0.118 
Age-related macular degeneration 17 0.176 0.059 0.118 0.059 0.176 0.176 0.000 
Total 153 0.229b 0.180d 0.029d 0.124d 0.212d 0.170d 0.056d 
*DB: disease burden, SI: Slovenian; SSc: systemic sclerosis; UK: British, a calculated from 17x4 DB evaluations b calculated from 153x4 DB evaluations. c calculated from 17x2 DB 







6.1.2. A detailed analysis of ’not relevant’ responses on the DLQI in psoriasis: 
potential biases in treatment decisions 
 
6.1.2.1. Characteristics of the patient population 
 
The mean age of patients with psoriasis (n = 428) was 49.2 (SD = 14.3) years and 65% 
of patients were male. Nearly one-third of the patients had tertiary education and less than 
one-third had a full-time job. A higher proportion of male patients performed paid work 
(62.6% vs. 44.7%, p <0.001), however, there was no significant difference between the 
sexes in terms of education. The mean disease duration was 19.9 and 12.3 years, 
respectively. More than 80% of patients had moderate-to-severe psoriasis, and the 
majority of patients (43.7%) received biologic therapy, another 25% received systemic, 
non-biological, and 24.1% received topical therapy only. A total of 31 patients (7.2%) 
did not receive any treatment at the time of the study, most had PASI values above 10, 
and were about to begin systemic therapy. 
 
6.1.2.2. Detailed analysis of the „not relevant” answers 
 
For the items sports (6), sexual difficulties (9), and work or study (7), 28.4%, 16.4%, and 
14% chose the NRR answers, respectively. Less than 3% indicated an NRR response for 













Figure 6. Distribution of DLQI items according to the number of ‘not relevant’ 





Of the 238 patients, 38.8% (n = 166) reported at least one NRR response. Of these, 84 
(19.6%) had one NRR response, 49 (11.5%) had two NRR responses, 22 (5.1%) had 3 
NRR responses, 7 patients (1.6%) had 4 NRR responses, 1 had (0.2%) indicated 5 NRR 
responses, 2 patients (0.5%) reported 6 NRR responses, and one patient (0.2%) reported 
eight NRR responses. Element 6 (sports) was marked by the majority of those who 
marked 1 NRR response (61.9%). 
Of the patients with a DLQI score of 0 or 1, 28% had at least one NRR response. Of the 
patients with DLQI scores of 2–5, 6–10, and 11–20, 38%, 52%, and 53% had NRR 
responses, respectively. For patients with a score above 21, the number of patients with 



































6.1.2.3. Determinant of the ’not relevant’ answers 
 
The mean DLQI scores of patients with NRR responses 1, 2, and 3 were 6.5, 7.2, and 7.3, 
respectively (p = 0.049). In our multivariate logistic regression model, several socio-
demographic and clinical factors showed a significant effect on NRR responses. Women 
were more likely to choose an NRR response. However, the existence of secondary or 
tertiary education reduced the likelihood of giving NRR responses. Full-time employed 
respondents were less likely to opt for the NRR response option. Furthermore, higher age 





























0-1 2-5 6-10 11-20 21-30
DLQI score
0 NRR 1 NRR 2 NRR 3 NRR 4 NRR
N=148 N=95 N=71               N=90               N=24
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Table 4. Multivariate, logistic regression model 
 
 Variable Coefficient SE 




Constant -1,668 0,599 0,189 0,005 
Gender (women) 0,498 0,235 1,646 (1,039–2,608) 0,034 
Age (years) 0,048 0,009 1,049 (1,031–1,068) 0,000 
PASI score 0,030 0,012 1,030 (1,006–1,055) 0,014 
Level of education 
Secondary -0,905 0,337 0,405 (0,209–0,784) 0,007 
Higher -0,071 0,377 0,343 (0,164–0,717) 0,004 
Working full-time -0,746 0,250 0,474 (0,290–0,774) 0,003 
n=428, dependent variable: 0 NRR response=”0”, at least 1 NRR response=”1” 
 
6.1.3. The health state and productivity of the Hungarian general population 
 
6.1.3.1. Characteristics of the sample 
 
A total of 2023 respondents participated in the study, 50.1% of the respondents (n = 1013) 
were women. The mean age was 48.7 years (SD = 17.9). 41.7% of the respondents had a 
primary education, 38.1% a secondary education and 20.2% a higher education. 19.7% 
of the respondents lived in Budapest, 52.5% in other cities and 27.8% in villages. The 
household of the filling persons had an average of 2.5 (SD = 1.3) members and the 
average monthly income of the household per capita was 128,000 HUF (SD = 60,000 
HUF). 
 
6.1.3.2. Health state 
 
EQ-5D-5L 
The mean of the EQ-5D-5L index score was 0.92 (SD = 0.15). Most problems were 
reported by respondents in the Pain / discomfort dimension: 31.6% indicated the existence 
of some level of problem in this dimension. The mean EQ-VAS was 81.6 (SD = 17.4) 
among participants. (Table 6.) 
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Men reported fewer problems than women, with the exception of the Self-care dimension, 
in which 9.9% and 8.9%, indicated some level of problem respectively. Respondents had 




Altogether 20.6% of respondents rated their current health status as “Very Good” and 
only 18 respondents (0.9%) stated that their health status was “Very Poor”. 31.4% of the 
respondents (n = 635 people) had a chronic illness or health problem lasting more than 6 
months. The majority of respondents (80.4%, n = 1627 people) were not limited by their 
health problems for more than 6 months, and 3.2% (n = 65 people) indicated that they 
were severely limited in their daily activities due to health problems. (Table 5) 
 
 
Table 5.  Respondents current health state (MEHM), N=2023 
 
Minimum European Health Module  n (%) 
Self-perceived health 
Very good 417 (20.6%) 
Good 916 (45.3%) 
Fair 545 (26.9%) 
Bad 127 (6.3%) 
Very bad 18 (0.9%) 
Chronic morbidity 
Yes 635 (31.4%) 
No 1381 (68.8%) 
Does not want to answer 7 (0.3%) 
Activity limitations 
Severely limited 65 (3.2%) 
Limited but not severely 329 (16.3%) 
Not limited 1627 (80.4%) 








Participants worked a median of 40 hours (minimum-maximum: 0-100) hours in the week 
prior to completing the questionnaire and had a median of 0 hours of absence due to health 
reasons. The maximum number of hours missed from work was 60 hours (minimum: 0 
hours). The median score of absenteeism and presenteeism, and total productivity loss at 
work, were both 0. 
Regarding the questions on employment, 1259 people answered that they work full-time 
or part-time. Based on the answers to the first question of the WPAI questionnaire, 1232 
respondents were in paid employment at the time of the questionnaire survey, the 
differences may be due to different questions (e.g. if a self-employed respondents 
indicated that they are not in paid employment). The work-related analyses were based 
on the responses of 1232 people based on the WPAI questionnaire. 
In addition, an additional 4 respondents were excluded from our analysis because the 
maximum number of hours of possible paid work was 100 hours per week. Another 32 
people did not work last week, but not for health reasons. Two participants were excluded 
due to incomplete responses (the question on disability at work was not completed, but 
they reported that they worked last week). Our analysis on paid work involved of 1194 
respondents. Of these, 25 people did not work, so the decrease in productivity during 
work was analysed for 1169 people. 
The average WPAI productivity loss in other activities was 9.5% (SD = 21.0%), while 
the average value of total productivity loss at work was 7.7% (SD = 20.9%). For 
absenteeism and presenteeism, the mean values were 3.6% (16.4%) and 4.4% (14.2%), 
respectively. We did not find significant differences by gender, we found similar values 
for women and men in all four variables. According to our analysis by age groups, we 
found a significant difference between the mean value productivity loss in other activities, 





Table 5. Respondent’s socio-economic characteristics and productivity 
 








WPAI, absenteeism, % 
N=1194 
WPAI total 
productivity loss % 
N=1194 
WPAI presenteeism, %, 
N=1169 
Mean (SD) Mean (SD) Mean (SD) N (%) Mean (SD) Mean (SD) N (%) Mean (SD) 
Total sample 2023 (100%) 0.877 (0.204) 81.6 (17.4) 9.5 (21.0) 1194 (100%) 3.6 (16.4) 7.7 (20.9) 1169 (100%) 4.4 (14.2) 
Gender  p=0.857 p=0.012 p=0.222  p=0.448 p=0.651  p=0.879 
Men 1010 (49.9%) 81.6 (17.4) 0.886 (0.201) 8.9 (20.2) 614 (51.4%) 4.1 (17.3) 8.0 (21.2) 600 (51.3%) 4.3 (1.3.7) 
Women 1013 (50.1%) 81.6 (17.4) 0.868 (0.207) 10.2 (21.8) 580 (48.5%) 3.1 (15.4) 7.3 (20.6) 569 (48.7%) 4.7 (15.5) 
Age group  p=0.000 p=0.000 p=0.000  p=0.983 p=0.000  p=0.000 
18-24 208 (10.3%) 92.6 (10.3) 0.923 (0.100) 1.8 (9.6) 111 (9.3%) 4.1 (16.7) 6.0 (20.4) 109 (9.3%) 2.4 (12.9) 
25-34  308 (15.2%) 90.7 (11.5) 0.957 (0.117) 3.3 (14.0) 249 (21.7%) 3.7 (17.2) 7.5 (22.4) 243 (20.8%) 4.3 (16.1) 
35-44  387 (19.1%) 86.5 (13.6) 0.928 (0.174) 4.2 (13.9) 329 (27.6%) 3.2 (15.0) 6.9 (19.4) 324 (27.7%) 4.0 (13.2) 
45-54 333 (16.5%) 85.1 (14.1) 0.925 (0.159) 5.3 (16.0) 296 (24.8%) 3.7 (16.7) 7.4 (20.6) 289 (24.7%) 3.9 (13.0) 
55-64  334 (16.5%) 76.6 (17.6) 0.856 (0.201) 11.7 (22.5) 190 (15.9%) 4.1 (17.6) 9.7 (22.2) 185 (15.8%) 6.0 (14.8) 
65-74  267 (13.2%) 70.3 (17.1) 0.772 (0.216) 16.8 (24.7) 19 (1.6%) 2.6 (11.5) 14.5 (2.1.8) 19 (1.6%) 13.7 (19.2) 
75-84  145 (7.2%) 60.3 (16.9) 0.661 (0.235) 30.3 (28.9) - - - - - 
85- 41 (2.0%) 57.0 (20.4) 0.549 (0.332) 42.9 (32.0) - - - - - 
Education  p=0.000 p=0.000 p=0.000  p=0.118 p=0.102  p=0.436 
Primary 844 (41.7%) 75.8 (19.8) 0.828 (0.235) 14.8 (25.8) 400 (33.5%) 4.8 (19.3) 9.7 (24.2) 387 (33.1%) 5.2 (16.1) 
Secondary 770 (38.1%) 85.6 (14.4) 0.908 (0.176) 5.9 (16.4) 511 (42.8%) 3.5 (15.8) 7.5 (20.5) 502 (42.9%) 4.5 (14.4) 
Higher 409 (20.2%) 86.1 (13.4) 0.921 (0.160) 5.4 (14.5) 283 (23.7%) 2.2 (12.5) 5.0 (15.9) 280 (24.0%) 2.9 (10.4) 
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WPAI. absenteeism. % 
N=1194 
WPAI total 
productivity loss % 
N=1194 
WPAI presenteeism. %. 
N=1169 
Mean (SD) Mean (SD) Mean (SD) N (%) Mean (SD) Mean (SD) N (%) Mean (SD) 
Mother’s education  p=0.000 p=0.000 p=0.000  p=0.015 p=0.009  p=0.187 
Primary 1283 (63.4%) 78.0 (18.9) 0.840 (0.227) 12.8 (24.0) 659 (55.2%) 4.8 (18.9) 9.6 (23.6) 640 (54.7%) 5.2 (15.6) 
Secondary 509 (25.2%) 87.3 (12.5) 0.938 (0.142) 3.9 (12.5) 365 (30.6%) 2.1 (12.8) 4.9 (15.9) 360 (30.8%) 2.9 (9.9) 
Higher 231 (11.4%) 89.3 (11.3) 0.949 (0.121) 4.0 (13.4) 170 (14.2%) 2.1 (11.8) 5.9 (18.6) 169 (14.5%) 4.5 (15.9) 
Residence  p=0.004 p=0.004 0.271  p=0.268  p=0.158  p=0.334 
Budapest 399 (19.7%) 85.5 (14.2) 0.901 (0.187) 6.1 (14.3) 263 (22.0%) 2.3 (13.4) 4.8 (15.0) 259 (22.2%) 2.6 (7.4) 
Other city 1062 (52.5%) 80.8 (17.8) 0.871 (0.199) 10.1 (21.9) 613 (51.3%) 3.8 (16.4) 7.8 (21.0) 601 (51.4%) 4.2 (14.0) 
Other 562 (27.8%) 80.4 (18.4) 0.871 (0.224) 10.9 (23.2) 318 (26.7%) 4.3 (18.5) 9.7 (24.4) 309 (26.4%) 6.0 (18.1) 
Marital status  p=0.000 p=0.000 p=0.000  p=0.921 p=0.004  p=0.000 
Married 939 (46.4%) 81.4 (16.5) 0.891 (0.179) 8.0 (18.5) 576 (48.2%) 3.2 (14.5) 6.4 (18.0) 568 (48.6%) 3.4 (11.3) 
In a relationship 301 (14.9%) 88.6 (13.1) 0.940 (0.141) 3.9 (14.2) 241 (20.2%) 5.4 (21.0) 9.3 (25.1) 232 (19.8%) 4.4 (16.3) 
Single 387 (19.1%) 88.3 (14.4) 0.933 (0.174) 4.6 (15.9) 259 (21.7%) 2.9 (14.5) 6.6 (19.4) 255 (21.8%) 3.9 (13.6) 
Widow 207 (10.2%) 65.4 (18.7) 0.658 (0.277) 2.9 (30.5) 17 (1.4%) 5.9 (24.3) 18.8 (30.4) 16 (1.4%) 13.8 (22.8) 
Divorced 185 (9.1% 75.5 (18.1) 0.835 (0.208) 15.1 (25.7) 100 (8.4%) 3.5 (17.8) 12.0 (26.0) 97 (8.3%) 9.2 (21.0) 
Other 4 (0.2%) 73.8 (23.6) 0.802 (0.233) 12.5 (25.0) 1 (0.1%) 0.0  0.0 1 (0.1%) 0.0 
Married/Living in a 
relationship 
 p=0.000 p=0.000 p=0.000  p=0.289 p=0.263  p=0.044 
no 783 (38.7%) 79.1 (19.2) 0.837 (0.242) 13.5 (25.1) 377 (31.6%) 3.2 (15.9) 8.5 (22.1) 369 (31.6%) 5.7 (16.5) 
yes 1240 (61.3%) 83.2 (16.0) 0.903 (0.172) 7.0 (17.6) 817 (68.4%) 3.8 (16.7) 7.2 (20.4) 800 (68.4%) 3.7 (13.0) 
* Four respondents did not answer all five questions in the descriptive part of the EQ-5D-3L, so their EQ-5D-3L index value could not be calculated for them. ** A total of 
1232 respondents did paid work, but 32 of them answered that 0 worked hours due to health problems and worked 0 hours last week. In another 27 cases, there was a missing 






ICECAP-A and ICECAP-O 
 
In the ICECAP-A questionnaire (used for those under 65 years of age (n = 1568)), the 
highest levels of abilities were found in the dimensions of Attachment, Enjoyment, and 
Autonomy (59.4%, 56.6%, and 52.6%, respectively). The Outcomes and Progress 
dimension was not problematic for 43.4% of respondents, and only about half (51.8%) of 
respondents felt secure in all areas of life. 
The ICECAP-O questionnaire was for those aged 65 and over (453 respondents in our 
sample). Nearly two-thirds (64.9%) of respondents in the Attachment dimension reported 
some level of problem. In the Enjoyment dimension, this proportion was even higher: 
78.4% indicated the existence of any problem. Control (independence) was a problem for 
the majority (71.1%), and Role (the ability to do valuable things) were generally present 
(72.8%) as well as Security (thinking about the future without concern) (75, 7%). (Figures 
8. and 9.) 
Differences by gender were small for both ICECAP questionnaires. The mean of the 
ICECAP-A index was 0.89 (SD = 0.13), even the mean of the ICECAP-O (over 65 years) 










Figure 8. ICECAP-A answers by gender (%) 
 
0% 10% 20% 30% 40% 50% 60% 70%
I am able to feel settled and secure in all areas of my life
I am able to feel settled and secure in many areas of my life
I am able to feel settled and secure in few areas of my life
I am unable to feel settled and secure in any areas of my life
I can have a lot of love, friendship and support
I can have quite a lot of love, friendship and support
I can have a little  love, friendship and support
I cannot have any love, friendship and support
I am able to be completely independent
I am able to be independent in many things
I am able to be independent in a few things
I am unable to be at all independent
 I can achieve and progress in all aspects of my life
 I can achieve and progress in many aspects of my life
 I can achieve and progress in few aspects of my life
 I cannot achieve and progress in any aspects of my life
I can have a lot of enjoyment and pleasure
I can have quite a lot of enjoyment and pleasure
I can have quite a little enjoyment and pleasure












































































Figure 9. ICECAP-O answers by gender (%) 
 
0% 10% 20% 30% 40% 50% 60% 70%
I can have all of the love and friendship that I want
I can have a lot of the love and friendship that I want
I can have a little of the love and friendship that I want
I cannot have any of the love and friendship that I want
I can think about the future without any concern
I can think about the future with only a little concern
I can only think about the future with some concern
I can only think about the future with a lot of concern
I am able to do all of the things that make me feel valued
I am able to do many of the things that make me feel valued
I am able to do a few of the things that make me feel valued
I am unable to do any of the things that make me feel valued
I can have all of the enjoyment and pleasure that I want
I can have a lot of the enjoyment and pleasure that I want
I can have a little of the enjoyment and pleasure that I want
I cannot have any of the enjoyment and pleasure that I want
I am able to be completely independent
I am able to be independent in many thing
I am able to be independent in a few things












































































6.1.3.5. Correlations between different measures 
 
To explore the relationship between respondent health, well-being, and productivity, we 
calculated Spearman’s rank correlation. We found a significant negative relationship 
between the EQ-5D-5L index score and the WPAI absenteeism (r = -0.116), presenteeism 
(r = -0.399), total productivity loss at work (r = -0.371), and productivity loss in other 
activities. (r = -0.593) (p <0.001 in all cases). The EQ-5D-3L values showed very similar 
results: r = -0.116, r = -0.387, r = 0.359, and r = -0.592, respectively (p <0.001 in each 
case). Out of the WPAI values, the participants’ household net monthly income showed 
a significant relationship only with the productivity loss in other activities (r = -0.277, p 
= 0.000). ICECAP-A and ICECAP-O values showed a significant negative relationship 
with WPAI. The age of the respondents showed a positive significant relationship 
between presenteeism (r = 0.141), total productivity loss at work (r = 0.113) and 





Table 6. Correlations of the different measures  








loss at work (%) 
Productivity loss 














r 1               
p 0.000               
Presenteeism (%) 
r 0.147** 1             
p 0.000 0.000             
Total productivity loss 
at work (%) 
r 0.585** 0.900** 1           
p 0.000 0.000 0.000           
Productivity loss in 
other activities (%) 
r 0.134** 0.768** 0.660** 1         
p 0.000 0.000 0.000 0.000         
EQ-5D-5L index score 
r -0.116** -0.399** -0.371** -0.593** 1       
p 0.000 0.000 0.000 0.000 0.000       
EQ-5D-3L index score 
r -0.116** -0.387** -0.359** -0.592** 0.918** 1     
p 0.000 0.000 0.000 0.000 0.000 0.000     
Age 
r 0.008 0.141** 0.113** 0.412** -0.500** -0.490** 1    
p 0.782 0.000 0.000 0.000 0.000 0.000 0.000    
Net monthly income of 
the household 
r -0.024 -0.029 -0.035 -0.277** 0.381** 0.383** -0.371** 1   
p 0.496 0.415 0.33 0.000 0.000 0.000 0.000 0.000   
ICECAP-A 
r -0.070* -0.212** -0.196** -0.281** 0.469** 0.462** -0.210** 0.221** 1  
p 0.016 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000  
ICECAP-O 
r -0.515* -0.578** -0.585** -0.490** 0.613** 0.589** -0.179** 0.236** - 1 
p 0.017 0.006 0.005 0.000 0.000 0.000 0.000 0.000 - 0.000 
*significant on a 0.05 level 
** significant on a 0.01 level
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6.1.4. Characteristics and determinants of informal care in chronic diseases in 
Hungary: A comparative analysis 
 
6.1.4.1. Patients in the sample 
 
A total of 14 different studies met our selection criteria, all of which were performed at 
different diagnoses. The studies covered a wide range of diseases: psoriatic arthritis (AP) 
(Brodszky et al., 2009), age-related macular degeneration (AMD) (Péntek et al., 2012a), 
dementia (Érsek et al., 2010), endometriosis (Simoens et al., 2012), epilepsy (Pentek et 
al., 2013), bladder cancer (Hever et al., 2015), benign prostatic hyperplasia (BPH) (Rencz 
et al., 2015c), osteoporosis (Péntek et al., 2016b), Parkinson’s disease (Tamás et al., 
2014), psoriasis (Rencz et al., 2014, Balogh et al., 2014), rheumatoid arthritis (RA) 
(Péntek et al., 2007), systemic sclerosis (SSc) (Minier et al., 2010), multiple sclerosis 
(SM) (Péntek et al., 2012b), schizophrenia (Gulácsi et al., 2012).  
A total of 2,047 patients were included in the sample, with a mean age of 58.9 (SD = 
16.3) years. 58.0% of the patients were female, with a mean age of 57.8 (SD 16.7) years 
and a male age of 60.3 (SD = 15.6) years. The three diagnoses with the highest number 
of patients were osteoporosis (n = 282), RA (n = 255), and benign prostate hyperplasia (n 
= 246). (Table 8.) 
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Total 2047 58.04% 58.88 (16.34) 23.98% 31.34% 8.94 (9.17) 0.64 (0.33) 60.48 (20.25) 
Osteoporosis (Péntek et al., 2016b) 282 100.00% 69.58 (8.58) 23.32% 67.38% 7.28 (5.34) 0.58 (0.32) 58.96 (17.06) 
Rheumatoid arthritis (Péntek et al., 2007) 255 85.83% 55.45 (12.31) 16.80% 22.00% 9.10 (9.27) 0.46 (0.33) 51.65 (19.81) 
Benign prostatic hyperplasia (Rencz et al., 2015c) 246 0% 70.59 (8.13) 25.62% 12.30% 5.56 (4.86) 0.85 (0.19) 68.37 (15.54) 
Psoriasis (Balogh et al., 2014) 200 32.00% 50.66 (12.93) 20.00% 34.50% 21.44 (11.69) 0.69 (0.31) 64.43 (21.34) 
Psoriatic arthritis (Brodszky et al., 2009) 183 57.38% 50.15 (12.92) 23.63% 20.22% 9.24 (9.24) 0.47 (0.35) 54.68 (20.01) 
Bladder cancer (Hever et al., 2015)  151 35.10% 66.25 (9.58) 18.79% NA 3.57 (3.74) 0.79 (0.24) 67.80 (19.34) 
Age-related macular degeneration (Péntek et al., 2012a) 122 62.30% 75.16 (7.88) 25.62% 35.54% 2.94 (2.54) 0.66 (0.33) 58.59 (16.43) 
Parkinson’s disease (Tamás et al., 2014) 110 34.29% 63.28 (11.26) 36.36% 21.70% 8.22 (5.78) 0.59 (0.28) 59.32 (17.92) 
Epilepsy (Pentek et al., 2013) 100 58.00% 36.65 (12.49) 18.00% 47.00% 15.45 (12.12) 0.80 (0.29) 73.84 (15.85) 
Dementia (Érsek et al., 2010) 88 59.77% 77.55 (8.52) 13.64% 18.60% NA 0.39 (0.33) 48.59 (23.87) 
Endometriosis (Simoens et al., 2012) 84 100% 32.80 (4.73) 55.95% 14.29% 8.00 (6.46) 0.90 (0.12) NA 
Systemic sclerosis (Minier et al., 2010) 80 90.00% 57.39 (9.60) 20.00% 27.50% 7.16 (6.63) 0.58 (0.29) 56.25 (18.73) 
Schizophrenia (Gulácsi et al., 2012) 78 46.15% 44.24 (13.05) 11.54% NA NA 0.64 (0.29) 60.01 (24.71) 




More than half (59.9%) of the osteoporosis shad fractures, and 4.3% had femoral fractures 
(Péntek et al., 2016b). In benign prostatic hyperplasia the average  International Prostate 
Symptom Score was 12.8 (SD=6.3) (Rencz et al., 2015c).  
 
The proportion of those receiving biologic therapy at the time of the survey was 83.6% 
in macular degeneration in old age, 51.5% in psoriasis, 6.0% in AP, and 0% in RA (Péntek 
et al., 2012a, Brodszky et al., 2009, Péntek et al., 2007, Balogh et al., 2014). In the bladder 
cancer group, 13.2% of patients underwent cystectomy and 2.0% received palliative 
therapy only (Hever et al., 2015). Almost one half (45.5%) of the Parkinson’s disease 
group belonged to categories I-II of the Hoehn & Yahr scale, which measures the severity 
of the disease (Tamás et al., 2014). The majority (60.8%) of the epilepsy group had 
seizures in the 12 months prior to the survey (Pentek et al., 2013). The mean Mini Mental 
Test value for patients with dementia was 16.70 (SD = 7.24)(Érsek et al., 2010). In 
systemic sclerosis, the proportion of diffuse cutaneous subgroup was 25.0%  (Minier et 
al., 2010). In endometriosis, 26.2% of patients were treated surgically (Simoens et al., 
2012). In schizophrenia, 39.7% of patients were in the more than moderate category as 
measured by the Global Clinical Scale (Gulácsi et al., 2012). The mean value of the 
Expanded Disability Status Scale in multiple sclerosis was 1.9 (SD 1.7) (Péntek et al., 
2012b). 
 
6.1.4.2. Informal care use 
 
A quarter (27.4%) the of patients indicated that they had received informal care, with 
rates ranging from 6.5% (benign prostatic hyperplasia) to 87.2% (dementia) in various 
diseases. More than one-third of patients received informal care for dementia (87.2%), 
rheumatoid arthritis (49.8%), systemic sclerosis (38.8%), psoriatic arthritis (37.7%) and 









Figure 10. The rate of patients receiving informal care (%) by diagnosis and age 
 
 
RA: rheumatoid arthritis, SSc: systemic sclerosis, AP: psoriatic arthritis, SM: multiple sclerosis, AMD: 
age-related macular degeneration, BPH: benign prostatic hyperplasia 
 
The average number of hours of informal care per week per illness is presented in Figure 
11. In our analysis (using a 24-hour / day limit), the average weekly number of hours in 
the total sample was 7.54 (SD = 26.36) hours. In only three diseases did the average 
duration of informal care exceed 10 hours per week, with a typically large variance (hours 
/ week): dementia (72.19, SD = 69.56), multiple sclerosis (18.79, SD = 35.47) and 
Parkinson's disease (12.57, SD = 31.45). The lowest weekly informal care time was 
observed in endometriosis, psoriasis and benign prostatic hyperplasia, with an average of 
less than 2 hours per week in all three cases (1.20, SD = 5.05; 1.36, SD = 12.11; and 1, 
respectively). 51, SD = 7.18 hours / week). Based on the results of the Kruskal-Wallis 
test, the differences between the groups are significant (p = 0.000). 
In our secondary analysis (using an 8-hour limit per day), informal care averaged 4.83 
hours per week (SD = 12.2 hours), with the mean number of hours in dementia and 
epilepsy decreasing the most compared to the primary analysis. (Figure 11) For both 
approaches, the average was above 5 hours / week in dementia, SM, Parkinson’s disease, 
RA, SSc, and AP. Based on the results of the Kruskal-Wallis test, the differences between 




Figure 11. Average time of informal care received per diagnosis (hours / week), using 
a limit of 24 or 8 hours per patient per day 
 
 
SSc: systemic sclerosis, AMD: age-related macular degeneration, BPH: benign prostatic hyperplasia 
 
 
6.1.4.3. Patients’ health status measured by the EQ-5D-3L questionnaire 
 
Looking at the overall sample, most patients indicated that they had some or severe 
problems in the Pain / discomfort, Mobility, and Anxiety / Depression dimensions 
(62.8%, 52.9%, 51.7%, respectively), of which severe the proportion of those reporting a 
severe problem was 10.7%, 0.7% and 7.3%, respectively. In the Self-care and Usual 
activities dimensions, 74.8% and 53.3% of patients indicated that they had no problem, 
respectively. In the Mobility dimension, RA, Parkinson's disease and AP patient groups 
had the highest rates of problems (82.2%, 81.9%, 79.9%, respectively) and also in the 
Self-care dimension (52.3%, 55.3%, and 48.9%). In the Usual activities dimension, 
patients suffering from SSc, AP, and RA reported the most problems (77.9%, 77.5%, 
75.8%, respectively). Pain / discomfort problems occurred at the highest rates in the RA, 
AP, and osteoporosis (91.9%, 90.6%, 87.7%, respectively), while problems in Anxiety / 
depression were most common in schizophrenia, SSc, and Parkinson's disease (76.9%, 
70.0% and 68.3%). 
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6.1.4.4. Comparison of informal care recipients and non-recipients 
 
Patients receiving informal care were on average 3.7 years older than those not receiving 
informal care. Approximately one-fifth (19.9%) of male patients received informal care, 
and almost one-third of women (32.5%). A slightly smaller proportion of patients living 
with family used informal care than people living alone (70.9% versus 75.6%). Regarding 
level of education, the share of those with primary or lower education was the highest, 
while the share of those with higher education was the lowest among those who received 









 mean (SD) / n (%) 
Did not receive 
informal care 
mean (SD) / n (%) 
Number of patients 1480 558 
Age 57.88 (16.46) 61.58 (15.60) 
Gender 
Women 797 (53.9%) 384 (69.4%) 
Men 682 (46.1%) 169 (30.6%) 
Living conditions 
Living alone 411 (32.8%) 133 (27.8%) 
Living with family 841 (67.2%) 346 (72.2%) 
Disease duration (years) 8.76 (9.15) 9.52 (9.23) 
Education 
Lower than primary 5 (0.4%) 4 (0.7%) 
Primary 275 (23.2%) 198 (36.7%)  
Specialized school 35 (3.0%) 12 (2.2%) 
Secondary 557 (47.0%) 233 (43.2%) 
Higher 312 (26.4%) 92 (17.1%) 
EQ-5D-3L index (-0,594 – 1) 0.73 (0.27) 0.42 (0.35) 
EQ VAS (0 - 100) 65.03 (18.71) 49.29 (19.56)  
 
 
The average disease duration was 0.76 years longer for those receiving informal care than 
for those not receiving informal care, however the difference was not significant (p = 
0.066). In all five dimensions of the EQ-5D-3L, the proportion of those who reported 
some or severe problems was higher among those receiving informal care than those who 
did not receive informal care. (Figure 12) The largest differences were in the Usual 
activities and Self-care dimensions (48.2% and 44.8%, respectively). To compare the 
health status of the two groups measured by the EQ-5D-3L index and EQ VAS, the Mann-
Whitney U test was used; 0.000). The average informal care time of the subgroup 










Figure 13. Average time of informal care (hours / week), using a limit of 8 or 24 








To explore the relationship between informal care time and patients’ quality of life, we 
calculated Spearman’s rank correlations. In the case of the EQ-5D-3L index and the EQ 
VAS, there was a negative, significant, but weaker-than-average relationship with the 
number of hours of informal care per week (r = -0.415, p = 0.000, and r = -0.328, p = 
0.000). 
6.1.4.5. Determinants of the informal care time 
 
A linear regression model was constructed to explore the factors explaining the weekly 
received informal care time. In our model variables expressing patients’ health status, 
demographics, and diagnosis dummy variables (in our model, the variable expressing RA 
was the basis for comparison) were included as explanatory variables. The EQ-5D-3L 
index (p = 0.002), EQ VAS (p = 0.000), gender (p = 0.044), and osteoporosis (p = 0.011) 
and Parkinson’s disease (p = 0.011) variables were significant. (Table 10) In the model, 
the value of the R2 was 0.062. 
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If the maximum informal care time (hours / week) limited in 8 hours a day was considered 
as the outcome variable, the explanatory variables were age (p = 0.017), gender (p = 
0.016), EQ VAS (p = 0.000), EQ-5D-3L index (p = 0.000) and dummy variables 
expressing the presence of some diseases were significant (Parkinson's disease p = 0.009; 
osteoporosis p = 0.000; age-related macular degeneration p = 0.021; psoriasis p = 0.029). 
In our model, the value of the R2 in this case was 0.111, that is, we can only estimate to a 
very limited extent the value of informal care used based on the explanatory variables we 
used. (Table 10.) 
 












Constant 7.909 3.088 -  2.562 0.011 
Age 0.060 0.041 0.057 1.477 0.140 
 Disease duration 0.027 0.054 0.016 0.505 0.613 
Gender 2.371 1.174 0.072 2.020 0.044 
EQ VAS  -0.091 0.025 -0.110 -3.615 0.000 
EQ-5D -4.840 1.543 -0.098 -3.138 0.002 
Psoriatic arthritis 1.434 1.655 0.029 0.866 0.386 
Psoriasis -1.641 1.892 -0.034 -0.867 0.386 
 Age-related macular degeneration -2.723 2.067 -0.047 -1.318 0.188 
Systemic sclerosis 1.468 2.065 0.021 0.711 0.477 
Osteoporosis -4.293 1.691 -0.091 -2.538 0.011 
Benign prostatic hyperplasia -0.281 2.031 -0.006 -0.138 0.890 
Epilepsy 4.160 2.197 0.065 1.893 0.059 
Parkinson’s disease 5.514 2.155 0.081 2.558 0.011 




6.2.1. Cost of informal care in chronic diseases in Hungary: A comparative 
analysis 
 
A total of 1,896 patients were enrolled in the 13 studies included in our analysis, with a 
mean age of 58.29 (SD = 16.62) years, of whom 59.9% were female, with a mean age of 
57.45 (SD 16.98) years. and 59.51 (SD = 16.01) years for men. The studies covered both 
major, high-prevalence diseases and less common diseases, with the three largest patients 
being osteoporosis (n = 282), RA (N = 255), and benign prostatic hyperplasia (N = 246). 
Patients had a mean EQ-5D-3L index of 0.629 (SD = 0.331) and a median = 0.725, with 
a mean EQ VAS of 59.87 (SD = 20.21) with a median of 60. 
A quarter (27.4%) of the patients received informal care, ranging from 6.5% (benign 
prostatic hyperplasia) to 87.2% (dementia) in various diseases. More than one-third of 
patients received informal care in dementia (87.2%), rheumatoid arthritis (49.8%), 
systemic sclerosis (38.8%), psoriatic arthritis (37.7%), and multiple sclerosis (36.8%).  
 
6.2.1.1. Informal care use of patients who reported a problem in the EQ-5D-3L 
dimensions 
The average informal care time of those patients, who reported some problems in the Self-
care dimension using a 24-hour limit was 8.13 (SD = 16.95) hours / week, and with an 8-
hour limit it was 7.33 (SD = 11.42) hours / week. 15.9% of those not receiving informal 
care reported some problems in this dimension. It important to mention the in the 
Mobility, Self-care and Usual activities dimensions the average informal care time per 




Table 10. Problems reported in the EQ-5D-3L dimension and informal care use 
 
EQ-5D dimension 
Patients who received informal care 
Weekly informal care time mean 
(SD) 
Patients who did not 
receive informal care 
(%) Maximized in 
weekly 56 hours 
Maximized in 
weekly 168 hours 
Mobility 
No problem 1.36 (6.32) 1.74 (10.42) 54.30% 
Some problem 5.10 (10.78) 6.55 (20.35) 45.40% 
Confined to bed 14.62 (16.81) 23.23 (44.94) 0.30% 
Self-care 
No problem 1.73 (6.91) 2.38 (13.36) 83.40% 
Some problem 7.33 (11.42) 8.13 (16.95) 15.90% 
Unable 19.28 (20.89) 34.86 (56.24) 0.60% 
Usual activities  
No problem 1.13 (5.90) 1.60 (11.27) 62.60% 
Some problem 5.37 (10.65) 6.50 (18.53) 35.20% 
Unable 11.58 (16.18) 17.69 (38.23) 2.20% 
Pain/discomfort 
No 1.85 (7.69) 2.29 11.86) 41.60% 
Moderate 3.73 (9.43) 4.74 (17.21) 51.20% 
Extreme  7.42 (11.95) 10.24 (26.80) 7.30% 
Anxiety/depression 
No 1.79 (6.73) 2.18 (10.98) 54.40% 
Moderate 4.71 (10.98) 6.41 (21.64) 40.60% 
Extreme  6.97 (10.81) 7.89(17.62) 5.00% 
 
 
6.2.1.2. Informal care use of the patients in the worst health states 
 
To identify patients with the worst health condition, we examined patients who had an 
EQ-5D-3L index value of 0 or lower, and 162 (9.1%) such patients were identified. Of 
whom, 26.1% had rheumatoid arthritis, 17.6% psoriatic arthritis, 13.9% dementia, and 
13.3% had osteoporosis. In endometriosis, there were no patients with an EQ-5D-3L of 0 
or lower. The mean age of those with the worst health status was 62.1 years (SD = 14.6 
years) and 66% were female. A third (31%) of those patients who had an EQ-5D-3L index 
value of 0 or lower lived alone. 
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Regarding informal care, 51 (31.5%) of those with the worst health status did not receive 
informal care and 15 of them lived alone. The average of informal care time was 18.71 
hours/week (SD = 39.43) using the 24-hour limit and 11.65 hour/week (SD = 16.79) using 
the 8-hour limit. The highest average weekly informal care time was observed in this case 
in dementia and Parkinson’s disease. Compared to those with an EQ-5D-3L index value 
higher than 0, the average number of hours of informal care for those in the worst health 




Table 11. Patients in the worst health states (N=165) by diagnosis* 
 
Diagnosis 
Informal care time hours/patient mean (SD) 
Patients in the worst health 
states ** 
Patients with an EQ-5D-3L 













Psoriatic arthritis  10.72 (9.98) 10.72 (9.98) 4.52 (10.53) 6.03 (20.88) 
Psoriasis 11.52 (17.93) 22.72 (51.80) 0.25 (1.09) 0.25 (1.09) 
Age-related macular 
degeneration 
1.33 (2.65) 1.33 (2.65) 2.83 (8.26) 2.83 (8.26) 
Rheumatoid arthritis 8.02 (11.51) 8.99 (16.42) 5.35 (9.78) 5.93 (14.08) 
Systemic sclerosis 2.33 (4.04) 2.33 (4.04) 5.79 (12.34) 7.42 (21.99) 
Dementia 39.63 (19.71) 79.21 (64.09) 31.21 (24.82) 69.77 (71.67) 
Osteoporosis 4.77 (7.31) 4.77 (7.31) 1.07 (4.85) 1.68 (12.61) 
Benign prostatic 
hyperplasia 
0*** 0*** 1.54 (7.05) 1.57 (7.32) 
Epilepsy 1.86 (2.73) 1.86 (2.73) 2.56 (10.34) 5.57 (27.02) 
Parkinson’s disease 6.33 (18.63) 18.78 (55.96) 8.87 (15.58) 12.07 (29.58) 
Schizophrenia 6.8 (9.55) 6.8 (9.55) 3.44 (6.64) 3.44 (6.64) 
Multiple sclerosis  5*** 5*** 13.91 (16.63) 19.39 (36.15) 
*In endometriosis, there were no patients whose EQ-5D-3L index score was lower than or equal to 0 
**EQ-5D-3L index score lower than or equal to 0 
***N=1  
 
6.2.1.3. The cost of informal care 
 
The weekly cost of informal care in our entire sample, using the 24-hour limit, was on 
average 7,399 HUF (SD = 25,648) and using the 8-hour limit per day, it was 4,696 HUF 
(SD = 11828) per patient. Based on the results of the Kruslkal-Wallis test, the costs differ 
significantly in different diagnoses according to both our primary and secondary analysis 


















Informal care recipients 








Psoriatic arthritis 183 37.7% 14130 (12527) 17288 (27474) 
Psoriasis 200 9.5% 8204 (12756) 13939 (36718) 
Age-related macular 
degeneration 
122 27.9% 9752 (12520) 9752 (12520) 
Rheumatoid arthritis 255 49.8% 11168 (11350) 12401 (17787) 
Systemic sclerosis  80 38.8% 14203 (15489) 18157 (30904) 
Dementia 86 87.2% 37218 (20899) 80530 (66503) 
Endometriosis 84 9.5% 12223 (11470) 12223 (11470) 
Osteoporosis 281 14.9% 8816 (11882) 14132 (34695) 
Benign prostatic hyperplasia 246 6.5% 22075 (15920) 22561 (16995) 
Epilepsy 100 13.5% 18876 (21152) 39743 (61801) 
Parkinson’s disease 109 31.8% 10376 (16208) 14642 (33074) 
Schizophrenia 78 30.8% 11554 (7181) 11554 (7181) 
Multiple sclerosis  24 36.8% 14374 (16120) 19947 (35678) 
 
The average cost of informal care was higher for female patients than for male 
patients, including the 24- and 8-hour limits: 4004 (SD = 11617) and 5144 (SD = 
11971) and 6827 (SD = 26522) and 7680 (SD = 25116) forint. Based on the results 
of the Mann-Whitney U test, the difference is significant in both cases (p <0.001 
in both cases). 
 
The cost of informal care for informal care users alone was average 24,509 HUF 
(SD = 42,281) per week, using the 24-hour limit, and 1,5,646 HUF (SD = 17,100) 
using the 8-hour limit per day. The highest cost is in dementia (using a 24-hour 
limit of 80530 HUF / patient / week and with an 8-hour limit of 37218 HUF / 
patient / week), the lowest cost was found in age -related macular degeneration 
(9752 HUF / patient / week) and endometriosis (12223 HUF / patient / week). 
However, the lowest cost using the 8-hour limit was observed in the case of 
psoriasis (8204 (SD = 12756) HUF / patient / week). (Table 13.) No significant 
difference by gender was found based on the results of the Mann-Whitney U test 




6.2.1.4. The determinants of informal care cost 
 
To explore the relationship between the variables, we calculated pairwise Spearman’s 
rank correlations. A weaker than average negative relationship was observed between the 
cost of weekly informal care and the EQ-5D-3L index expressing patients' quality of life 
(r = -0.415, p <0.001) and the EQ VAS value (r = -0.326, p <0.001), indicating that 
patients in a worse condition received more informal care. We found an extremely weak 
but significant correlation between the cost of informal care and age (r = 0.094, p <0.001), 
indicating that older patients received more informal care than younger ones. 
 
6.2.1.5. The yearly costs of informal care 
 
Table 14 shows the informal cost per patient per year for each disease, calculated with 
the 8-hour informal care time limit providing a more conservative estimate. The average 
annual costs per patient ranged from 125,635 HUF (psoriasis) to 5,233,482 HUF 




Table 13. Estimated informal care cost/patient/year (HUF) in Hungary 
 
Diagnosis Prevalence in Hungary 
Estimated number of 






0,1-0,3% (Brodszky et al., 
2009, Brodszky et al., 
2010d) 
20 000 858805 
Psoriasis 
0,73-2,9% (OEP, 2009, 
Balogh et al., 2014, 
Herszényi et al., Rencz et 
al., 2015b) 
181 500 125635 
Age-related macular 
degeneration 
0,1%-9,8% (Péntek et al., 
2017a, Colijn et al., 2017) 
115 390 426510 
Rheumatoid arthritis 
0,5% (Herszényi et al., Kiss 
et al., 2005, Lepp-Gazdag et 
al., 2002, Péntek et al., 
2007, Dorner et al., 2016) 
50 000 896645 
Systemic sclerosis 
0,7-48, 9/100 000 (Minier 
et al., 2010) 
24 800 887169 
Dementia 
1316/100 000 (Érsek et al., 
2010) 
131 995  5233482 
Endometriosis 
2-10% (Simoens et al., 
2012) 
600 000 187657 
Osteoporosis 
2,5-21,2%* (Hernlund et 
al., 2013, Raspe et al., 
1998) 
600 000 women and 




8-90%-a*** (Rencz, 2012) 




0,3-0,6% (EMMI, 2017, 
Pentek et al., 2013) 
45 000 393687 
Parkinson’s disease 
100-200/100 000 (OEP, 
2013, Olesen et al., 2012, 
Tamás et al., 2014) 
20 000 (Tamás et al., 2014) 1366661 




7000  2123978 
*Different prevalence based on gender and age 
**In our sample, 60% of the patients suffering from osteoporosis had a fracture 
***Prevalence: age 31-40: 8%, age 41-50: 20%, age 51-60: 50%, age 61-70: 70%, age 71-80: 80%, ages 






6.2.2. Cost-of-illness studies in nine Central and Eastern European countries 
 
6.2.2.1. Selection of the publications 
 
After excluding duplicates (n = 246), our search resulted in 607 potentially relevant 
publications, of which 55 were not fully available and a further 98 reviews were available. 
A further 282 publications did not include cost of illness data, 54 did not focus on the cost 
of a specific disease, and 67 reports reported the cost of a therapy/intervention. A total of 
50 studies matched our selection criteria from database search results. 
 
As a result of an additional search for local literature, 8 more articles were selected 
(Austria: n = 2, Bulgaria: n = 5, Hungary: n = 1). A total of 58 publications (sometimes 
covering results for several countries) were selected: Hungary (n = 24), Bulgaria (n = 16), 
Poland (n = 11), Czech Republic (n = 10), Austria (n = 9), Slovenia (n = 4), Croatia (n = 
3), Slovakia (n = 3) and Romania (n = 3). 
 
6.2.2.2. Characteristics of selected publications 
 
The majority of selected papers included results for one country (74%), however, 15 
studies reported results for more than one country, for a total of 83 country-specific results 
for the 58 selected papers. Three quarters of the publications were in English (n = 44) and 
except for 5 publications (Georgieva, 2015, Glogovska et al., 2010, Ivanova et al., 2014, 
Kyuchukov et al., 2015, Todorova, 2007) an English abstract was available for all non-
English language publications. The majority of publications reported costs in euros (n = 
45, 78%). A total of 37 publications converted the local currency into euros, of which 17 
(46%) provided the exchange rate, 5 (14%) the source of the exchange rate, and 15 (40%) 
publications did not provide information on the conversion at all. The reporting of cost 
data in local currency was the most common in Romania (67%). A total of 47 (81%) 
publications reported information on research funding. The lack of funding was most 
common in Romania (n = 2.67%) and Bulgaria (n = 5; 31%). 
By clinical area, “Endocrine, nutritional, and metabolic diseases” were the most common 
in the publications (n = 15 country-specific results), followed by “Neoplasms” (n = 12), 
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and “Certain infectious and parasitic diseases” (n = 10). (Figure 14.) A total of 48 different 
diseases were analysed in the 58 selected papers. 
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A: Distribution of country-specific results across clinical areas defined by ICD groups (n=83)  
B: Distribution of studies between clinical areas defined by ICD groups (n=58) 
 
 
6.2.2.3. Methods used in the selected publications 
 
The characteristics by country are summarized in Table 15. The data were mostly from 
retrospective, self-administered questionnaires (48%), followed by retrospective “claims 
data” analysis (14%) and prospective surveys (14%). Sample sizes ranged from n = 2 
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(small cohorts) to n = 127,512 (large population surveys). Of the 58 studies selected, 26 
(45%) reported aggregate results in all major cost categories (direct health, direct non-
health, and indirect costs). 
 
The majority of the selected research used a social perspective (52%) and 17% conducted 
the analysis from the perspective of the financer. In the publications where it was reported, 
bottom-up (38%) and top-down (21%) methods were most commonly used. Data on 
productivity loss were reported in 47 (81%) publications. The human capital (72%) and 
friction cost (23%) methods were most commonly used to assess productivity loss. More 
than half (58%) of the publications did not report unit costs at all. (Table 15.)
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Table 14. Characteristics of cost-of-illness studies 
 
Number of country specific results: N=83; Number of papers: N=58 
 Austria1 Bulgaria2 Croatia3 Czech Republic4 Hungary5 Poland6 Romania7 Slovakia8 Slovenia9 Total 
Number of publications 9 16 3 10 24 11 3 3 4 58 
English language 5 11 3 10 21 11 1 3 4 44 
Local language  4 5 0 0 3 0 2 0 0 14 
Search 
Electronic database  7 11 3 10 23 11 3 3 3 50 
Hand search 2 5 NA NA 1 NA NA NA NA 8 
Currency 
Euro 9 10 3 10 21 10 1 3 3 45 
National currency NA 6 0 0 3 1 2 0 1 13 
Data source 
Cross-sectional questionnaire 6 9 0 3 15 1 0 0 0 28 
Retrospective chart review 1 1 0 2 2 1 0 1 0 5 
I  Interview-based, prospective 3 2 0 1 0 3 1 0 0 8 
Retrospective claims data 0 0 0 1 5 3 1 1 0 8 
Multiple source 1 2 1 2 1 2 1 1 3 6 
Modelling 0 1 2 1 1 1 0 0 1 2 
NR 0 1 0 0 0 0 0 0 0 1 
Perspective 
Payer 2 2 2 2 2 3 0 1 2 10 
Societal 2 8 0 3 18 4 0 0 1 30 
Patient 2 0 0 0 0 0 0 0 0 2 
Hospital 0 5 0 0 0 0 1 0 0 6 
NR 5 1 1 5 4 4 2 2 1 13 
Costing 
Top-down 1 1 0 1 1 2 0 1 0 12 
Bottom-up 3 10 1 3 16 2 0 1 2 22 
NR 5 5 2 6 7 7 3 1 2 24 
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 Austria1 Bulgaria2 Croatia3 Czech Republic4 Hungary5 Poland6 Romania7 Slovakia8 Slovenia9 Total 
Methods of estimating indirect cost 
Human capital 5 8 0 3 18 7 0 1 1 34 
Friction cost 1 1 1 2 1 1 1 1 1 11 
NR 0 0 0 0 2 0 0 0 0 2 
N/A 3 7 2 5 2 3 2 1 2 11 
Informal care costs  
Market price  0 8 1 0 16 1 0 0 0 5 
Opportunity cost 1 1 0 3 2 1 1 1 1 3 
NR 2 0 0 2 0 1 0 0 0 20 
Other 1 0 0 0 0 0 0 0 0 1 
N/A 5 7 2 5 6 7 2 2 3 29 
Funding 
EU 1 8 0 0 9 1 0 0 0 13 
Pharmaceutical company 5 2 1 3 8 4 1 3 1 11 
Government 1 0 0 5 3 1 0 0 0 13 
Other 0 0 0 1 0 0 0 0 0 1 
No funding 2 1 2 1 4 3 0 0 2 11 
NR 1 5 0 0 0 3 2 0 1 11 
Cost/patient 
Direct healthcare cost 5 13 1 4 20 5 3 1 1 38 
Indirect 6 10 2 6 21 9 1 2 3 38 
Informal care 4 9 1 5 18 3 1 1 1 29 
Total 8 13 3 7 23 9 3 3 3 47 
Unit cost 
Reported 3 8 1 7 16 5 2 1 2 24 
Not reported 6 8 2 3 8 6 1 2 2 34 
NA: not available, NR:not-reported,1(Grabmeier-Pfistershammer et al., 2013, Kobelt et al., 2006, Leal et al., 2016, Prast et al., 2013, von Campenhausen et al., 2009, Willich et al., 2006, 
Dimai et al., 2012, Wagner, 2011, Wagner, 2012); 2(Kuhlmann et al., 2016, Iskrov et al., 2015, Jakubczyk et al., 2016, Leal et al., 2016, Valov et al., 2014, Georgieva, 2015, Glogovska et 
al., 2010, Ivanova et al., 2014, Kyuchukov et al., 2015, Todorova, 2007, Angelis et al., 2016c, Péntek et al., 2016a, Chevreul et al., 2016a, Lopez-Bastida et al., 2016a, Lopez-Bastida et al., 
2016b, Cavazza et al., 2016b); 3(Jakubczyk et al., 2016, Leal et al., 2016, Bauer et al., 2014); 4(Blahova Dusankova et al., 2012, Jakubczyk et al., 2016, Klimeš et al., 2014, Leal et al., 2016, 
Maresova et al., 2016, Mlcoch et al., 2017, Tichopad et al., 2016, Tichopad et al., 2013, Winter et al., 2010, Holmerova et al., 2016); 5(Brodszky et al., 2009, Gulácsi et al., 2007, Jakubczyk 
et al., 2016, Leal et al., 2016, Lopez-Bastida et al., 2016a, Minier et al., 2010, Péntek et al., 2012b, Rencz et al., 2015c, Tamás et al., 2014, Tichopad et al., 2016, Tichopad et al., 2013, 
Érsek et al., 2010, Péntek et al., 2007, Inotai et al., 2015, Lopez-Bastida et al., 2016b, Kuhlmann et al., 2016, Angelis et al., 2016c, Balogh et al., 2014, Pentek et al., 2013, Péntek et al., 
2012c, Cavazza et al., 2016b, Péntek et al., 2012a); 6(Czech et al., 2013b, Dubas-Jakobczyk et al., 2016, Jakubczyk et al., 2016, Jaworski et al., 2012, Kawalec et al., 2015, Leal et al., 2016, 
Lesniowska et al., 2014, Szmurlo et al., 2014, Tichopad et al., 2016, Tichopad et al., 2013, Czech et al., 2013a);  7(Leal et al., 2016, Stoicescu et al., 2007, Stambu et al., 2013); 8(Leal et al., 
2016, Tichopad et al., 2016, Tichopad et al., 2013); 9(Dzajkovska et al., 2007, Jakubczyk et al., 2016, Leal et al., 2016, Nerat et al., 2013)
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6.2.2.4. Comparing the costs of seleted individual diseases 
 
A total of 83 country-specific cost data were reported in selected publications, which 
included 48 different diseases. In addition to rare diseases, multiple sclerosis had the 
highest disease burden (average total cost per patient) in three countries (Austria 50,599 
EUR, Czech Republic 14,777 EUR and Poland 12,343 EUR) (Blahova Dusankova et al., 
2012, Kobelt et al., 2006, Szmurlo et al., 2014).  
In Hungary, schizophrenia (15,187 EUR) and gestational diabetes (32,263 EUR) were the 
highest-cost diseases in Bulgaria (Todorova, 2007, Péntek et al., 2012c).  
Multi-country research has been conducted in 9 diagnoses (rotavirus gastroenteritis, 
pneumonia, bladder cancer, hypoglycaemia, Duchenne muscular dystrophy, 
epidermolysis bullosa, Prader-Willi syndrome, cystic fibrosis, haemophilia). One study 
(bladder cancer) was included in the sample that reported results for all nine countries 
and an additional one (hypoglycaemia) for six countries. Two reports reported data for 
four different countries (rotavirus gastroenteritis and pneumonia) 
In the bladder cancer research, which included results from nine countries, the 
methodologies used in each country varied, with an average cost of 7,421 EUR (with 
country averages ranging from 2,320 EUR (Bulgaria) to 16,479 EUR (Slovenia)). 
Hypoglycaemia research, which included six countries and had an average total cost per 
patient (11 EUR), ranged from 5 EUR (Bulgaria) to 18 EUR (Slovenia) (Jakubczyk et al., 
2016).  
Separate but identical disease research has been found in eight diagnoses: multiple 
sclerosis, dementia, Parkinson’s disease, rheumatoid arthritis, osteoporosis, chronic 
obstructive pulmonary disease, systemic sclerosis, and diabetes.  
The most commonly discussed diseases were multiple sclerosis and diabetes, each 
appearing in multiple (four) studies (Kobelt et al., 2006, Péntek et al., 2012b). In the case 
of diabetes, the highest direct cost was found in Hungary (1,309 EUR), and the lowest in 
Bulgaria (472 EUR) (Nerat et al., 2013, Valov et al., 2014).  
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6.2.3.  Hungarian cost library 
6.2.3.1.Characteristics of selected publications 
Our  cost of illness search resulted in 105 items of which 26 was included (Angelis et al., 
2016b, Balogh et al., 2014, Brodszky et al., 2009, Chevreul et al., 2016a, Chevreul et al., 
2016b, Érsek et al., 2010, Gulácsi et al., Inotai et al., 2015, Jakubczyk et al., 2016, Lopez-
Bastida et al., 2016a, Lopez-Bastida et al., 2016b, Minier et al., 2010, Pentek et al., 2013, 
Péntek et al., 2016a, Péntek et al., 2012b, Péntek et al., 2012c, Péntek et al., 2007, Péntek 
et al., 2008, Rencz et al., 2015c, Tichopad et al., 2016, Tichopad et al., 2013, Horvath et 
al., 2014, Leal et al., 2016, Tamás et al., 2014, Angelis et al., 2016a). The cost-
effectiveness and budget-impact analysis search resulted in 79 publications, of which 
we included 25 publications  (Baji et al., 2012a, Baji et al., 2012b, Brodszky et al., 2014b, 
Dasbach et al., 2010, Iversen et al., 2015, Mandel et al., 2014, Marada et al., 2016, Nagy 
et al., 2014, Scuffham et al., 2006, Vokó et al., 2012, Zemplenyi et al., 2016, Boncz et 
al., 2010, Kovacs et al., 2014, Brodszky et al., 2010c, Daroczi et al., 2016). Altogether 13 
health technology assessments were included as a result of our hand-search (Brodszky et 
al., 2006a, Brodszky et al., 2006b, Brodszky et al., 2007, Brodszky et al., 2010b, Gulácsi, 
2010, Brodszky et al., 2010a, Brodszky et al., 2011a, Gulácsi et al., 2011, Brodszky et 
al., 2011b, Brodszky et al., 2011c, Brodszky et al., 2012, Brodszky et al., 2013, Brodszky 
et al., 2015{ ) along with seven additional Hungarian publications (Bodnár et al., 2010, 
Borsos et al., 2006, Brodszky et al., 2010e, Harangozó et al., 2008, József, 2006, Kárpáti 
et al., 2007, Kósa József et al., 2008). When updating our search, we found an additional 
314 publications, of which 14 was included in our analysis (Brodszky et al., 2020, Fejes 
et al., 2019, Vallejo-Torres et al., 2018, Trapero-Bertran et al., 2018, Németh et al., 2018, 
Coyle et al., 2018, Bocskai et al., 2018, Baji et al., 2018, Rencz et al., 2017, Péntek et al., 
2017b, Péntek et al., 2017c, Meszner et al., 2017, Kobelt et al., 2017, Brodszky et al., 
2017). 
The Hungarian cost library was created based on the 75 included publications. Out of the 
75 publications, we managed to extract 1289 cost items. The majority of the studies 
included (56%, n=42) were cost of illness articles. Altogether 1 health technology reports 
and 13 cost-effectiveness studies were identified. We included one (1,3%) budget impact 
analysis (Brodszky et al., 2014b), one (1,3%) cost-utility analysis  (Rencz et al., 2017) 
and one (1,3%) cost-minimization study (Kósa József et al., 2008) and 4 (5,3%) other 
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type of publications (Péntek et al., 2017c, Baji et al., 2012a, Baji et al., 2012b, Marada et 
al., 2016) in our analysis. 
The distribution of selected publications by year of publication is shown in Figure 15. 
Most of the identified publications were found in 2016 (n = 14), followed by 2010 (n = 
10) and 2014, (n = 7). Most of the identified publications in Hungarian were published 
in 2010 (n = 5). (Figure 15.) 
 




6.2.3.2. Clinical areas  
 
The selected publications covered a large number of different clinical areas. To 
cathegorise the publications, we used the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10 Version: 16) to evaluate the diseases / 
interventions they contain (ICD, 2016). Four of the selected publications (6.3%) were not 
related to a specific ICD main group.  These focused on informal payment (n=2) (Baji et 
al., 2012a, Baji et al., 2012b), different dental and oral surgeries (n=1) (Marada et al., 
2016), and the costs of anaesthesia (n=1) (Bocskai et al., 2018). 
The most common group was "Musculoskeletal and connective tissue disorders" (n=15, 
20,0%) (Brodszky et al., 2010b, Brodszky et al., 2011a, Gulácsi et al., 2011, Brodszky et 





























et al., 2014, Lopez-Bastida et al., 2016b, Minier et al., 2010, Péntek et al., 2007),  
„Neoplasms” (n=8, 12,0%) (Boncz et al., 2010, Brodszky et al., 2017, Dasbach et al., 
2010, Inotai et al., 2015, Leal et al., 2016, Vokó et al., 2012, Zemplenyi et al., 2016) and 
the „Diseases of the nervous system” (n=8, 10,7%) (Fejes et al., 2019, Kobelt et al., 2006, 






















I Certain infectious and parasitic 
diseases
II Neoplasms
III Diseases of the blood and 
blood-forming organs and certain 
disorders involving the immune 
mechanism 
IV Endocrine, nutritional and 
metabolic diseases 
V Mental and behavioural 
disorders   
VI Diseases of the nervous system   
XI Diseases of the digestive 
system
X Diseases of the respiratory 
system
XI Diseases of the digestive 
system
XII Diseases of the skin and 
subcutaneous tissue
XIII Diseases of the 
musculoskeletal system and 
connective tissue
XIV Diseases of the genitourinary 
system
XVII Congenital malformations, 
deformations and chromosomal 
abnormalities
XXI. Factors influencing health 






6.2.3.3. Distribution of publications: Hungarian studies and international research with 
the participation of Hungary 
 
The majority of the publications (62.7%, n = 47) were in English and 37.3% (n = 28) in 
Hungarian. The first author of 56 publications (74.7%) was Hungarian, and another 19 
publications (25.3%) were international. The distribution of the last authors was 69.3% 
(n = 52) Hungarian and 30.7% (n = 23) international. The majority of publications (n = 
51, 68%) were studies from Hungary and 32% (n = 24) international research with the 
participation of Hungary. 
 
6.2.3.4. Distribution of publications by Scimago ranking 
 
Of the publications, 33 (44%) were published in Scimago Q1 journals, 13 (17.3%) in Q2 
journals (Bocskai et al., 2018, Nagy et al., 2014, Brodszky et al., 2020, Rencz et al., 2017, 
Baji et al., 2012b, Rencz et al., 2015c, Brodszky et al., 2017, Jakubczyk et al., 2016, 
Dasbach et al., 2010, Brodszky et al., 2010c, Brodszky et al., 2009, Inotai et al., 2015, 
Tichopad et al., 2016), a further 5 articles (6.7%) (Marada et al., 2016, Péntek et al., 2008, 
Zemplenyi et al., 2016, Daroczi et al., 2016, Gulácsi et al.) were  Q3 and 7 articles (9.3%) 
were ranked Q4 (Kárpáti et al., 2007, Pentek et al., 2013, Péntek et al., 2012a, Fejes et 
al., 2019, Harangozó et al., 2008, Bodnár et al., 2010). A total of 4 articles (5.3%) were 
published in unlisted Hungarian journals (Brodszky et al., 2010e, Borsos et al., 2006, 
József, 2006, Kósa József et al., 2008). A further 13 technology analysis reports were 
selected as a result of our manual search (Brodszky et al., 2006a, Brodszky et al., 2006b, 
Brodszky et al., 2007, Brodszky et al., 2010a, Brodszky et al., 2010b, Gulácsi, 2010, 
2011a, 2011, Brodszky et al., 2011b, Brodszky et al., 2011c, Brodszky et al., 2012, 
Brodszky et al., 2013, Brodszky et al., 2015) which do not fall into the categories of the 











6.2.3.5. Costs in the publication 
 
The distribution of costs in the publications by outpatient and inpatient sector is shown in 
















Q1 Q2 Q3 Q4 Scimago által nem listázott magyar nyelvű közlések
110 
 





More than half of the publications (57.3%, n = 43) reported only direct costs, however, 
in three of the publications reporting indirect costs, the authors calculated the indirect 
costs after hospitalization and outpatient days, which is an estimate and cannot be 
considered as a methodologically appropriate indirect cost calculation (Jakubczyk et al., 
2016, Meszner et al., 2017, Tichopad et al., 2013). (Figure 19.) 
 
A total of 6 publications, reported cost data is cumulative over several years (Brodszky 
et al., 2017) for the whole patient population (Gulácsi et al., 2007, Horvath et al., 2014) 
or in the percentage of the respondents’ income (informal payment) (Baji et al., 2012a), 
in these cases, we estimated the average costs by calculating the number of years, the 























Figure 19. Distribution of the publications according to type of cost reported (%) 
 
*The study only reported indirect costs (Mandel et al., 2014)**N/A: two publications, which reported 
informal payments (Baji et al., 2012a, Baji et al., 2012b) 
 
 
6.2.3.6. Methodology of data collection (resource use) and methods of health economics 
analysis in selected publications 
 
The selected publications show highly heterogeneous methods of data collection, costing, 
and health economics, which include: 
The most common resource use data collection methodology in the selected publications 
was the use of a retrospective funding database and a cross-sectional study, used in a total 
of 57 publications (76%). 
1.retrospective NHIFA database 
Retrospective NHIFA database was used in 25 publications (33.3%), of which in 23 cases 
the authors performed an analysis of the health resources used in the given case solely on 
the basis of NHIFA data (Baji et al., 2018, Boncz et al., 2010, Borsos et al., 2006, 
Brodszky et al., 2011b, Brodszky et al., 2012, Brodszky et al., 2013, Brodszky et al., 
2015, Brodszky et al., 2017, Daroczi et al., 2016, Gulácsi et al., Horvath et al., 2014, 
Inotai et al., 2015, Iversen et al., 2015, Jakubczyk et al., 2016, Kárpáti et al., 2007, Leal 
et al., 2016, Rencz et al., 2017, Tichopad et al., 2013, Vokó et al., 2012, Colombo et al., 











Angelis et al., 2016a, Cavazza et al., 2016a, Cavazza et al., 2016b, Chevreul et al., 2016a, 
Chevreul et al., 2016b, Lopez-Bastida et al., 2016a, Lopez-Bastida et al., 2016b), and two 
publications used a combination of a retrospective funding database and a cross-sectional 
study (Brodszky et al., 2010b, Brodszky et al., 2006a). The use of health resources at 
different levels (primary care, outpatient and inpatient care, medicines, medical devices) 
was retrieved from NHIFA databases by the authors. For example, what resources were 
used in the treatment of prostate cancer (how many inpatients were admitted to care, what 
medications were used). 
 
2. retrospective NHIFA database supplemented by the results of a cross-sectional study 
We identified in two publications (2.7%) in which the use of the retrospective database 
was supplemented by the results of a cross-sectional study of the authors. 
 
3.cross-sectionnal survey 
A total of 34 publications (45.4%) included cross-sectional studies, of which 32 used only 
cross-sectional studies and two publications used a combination of retrospective review 
of financer’s database and cross-sectional study (Gulácsi, 2010, Brodszky et al., 2006a). 
In the cross-sectional studies, the authors asked in a questionnaire about the use and 
number of primary care, outpatient and inpatient care, medicines and medical devices (for 
example: how many times the patient visited their GP during the survey period) and only 
partially by social security. or use services and products that are not supported at all. 
Thereafter, if the service or product in question was subsidized by social security, the 
financing data of NHIFA were taken into account. In case the service and product were 








4. retrospective chart review 
In the case of chart reviews, the authors used the documentation of elected hospitals. The 
resources used (for example: diagnostic tests, x-rays) were recorded and categorized into 
a disease group (HBCS) category, and valued with the financial value of that given group. 
This provides a more detailed, more accurate picture, than simply relying on the NHIFA’s 
data, however the categorization made by the authors might not reflect the real category 
based on which the financing is provided.  
A total of 4 (n=5.3%) publications used chart reviews (Fejes et al., 2019, Meszner et al., 
2017, Tichopad et al., 2016, Vallejo-Torres et al., 2018). 
 
5.expert opinion 
6.7% (n = 5) of the selected publications referred to expert opinion as a methodology of 
(resource use) data collection (Coyle et al., 2018, Kovacs et al., 2014, Nagy et al., 2014, 
Németh et al., 2018, Trapero-Bertran et al., 2018).  
 
6.micro-costing 
During the micro-costing, the authors performed exact identification, measurement and 
valuation of the resources used. In our analysis, one publication reported that they used 
micro-coting (Zemplenyi et al., 2016). 
 
7. quasi micro-costing 
A publication using a quasi-micro-costing was also selected, in which the authors 
calculated the financed price of diagnostic interventions based on NEAK data, drug use 
data based on the patient's medical records and the gross purchase price, special 
tuberculocids and hotel costs were identified based on data obtained from the hospital 





8.published randomized clinical trials  
A total of 7 publications (9.3%) were based on a published clinical trials (Brodszky et al., 
2011a, Brodszky et al., 2010c, József, 2006, Kósa József et al., 2008, Scuffham et al., 
2006, Brodszky et al., 2007). Cost calculation based on a randomized controlled clinical 
trial, in which, in the case of the group of patients described in RCT, the authors forint 
the processes and treatment in RCT. This is a first approximation before a medicine or 
other product enters the market, but neither the characteristics of the healthcare in a given 
country nor the impact of real circumstances are taken into account, so the results of these 
analyses can only be applied with great caution in practice. 
 
9. Central Statistical Office 
One of the selected publications (1.3%) used a household panel of the Central Statistical 
Office for data collection, in this publication the informal health expenditure of 
households was surveyed (Baji et al., 2012a).  
 
The indirect cost estimates also appeared in publications in several different ways: 
1.Indirect cost calculation: an estimate of the indirect costs incurred by the patient due to 
reduced productivity 
2.Limited indirect cost calculation: in some publications, the indirect cost was calculated 
by the authors after hospitalization and outpatient days, which may have led to an 
underestimation of indirect costs. 
 
6.2.3.7. Data sources for cost data reported in publications 
 
The cost data used in the publications also come from a number of different sources and 







Regarding the source of cost data, a total of 80% (n = 60) of the publications included the 
National Health Insurance Fund Manager (NHIFA) and its predecessors as the source of 
cost data (primary care, outpatient and inpatient care, drug and medical device databases). 
These are the official funding figures from which NIHIFA calculates the actual funding 
amounts. 
The issue of the widespread use of NIHFA data raises a number of important questions, 
the most important of which is the relationship between NHIFA financing and the real 
costs. Unfortunately, we cannot answer this question, but it is likely that the difference is 
significant, for the following reasons: 
It is based on funding data from NIHIFA and its predecessors, in which case the problem 
arises that the funding data do not contain a significant health economically significant 
factor. 
The collection of real hospital cost data needed to calculate the disease groups’s values 
(HBCS values) has been slow for the past two decades, the system, which had been 
introduced in 1993m has not been modified majorly since 1999 (changing the proportions 
of the groups), and last comprehensive hospital cost survey last took place in 2008 (Balázs 
et al., 2015). 
The hospital’s prospective funding is not only a funding mechanism but also a health 
policy tool, as it is not intended to reimburse the exact costs either at the hospital level 
(the costs of the same interventions can vary significantly between hospitals) or at the 
national level. 
In addition, the data is modified to an unknown extent in several cases, as service 
providers optimize their data provision to NHIFA, after which NHIFA checks, filters and 
modifies it. 
In Hungary, this financing database are available, but must be handled with care, because 






2. Wholesale price 
Wholesale price as a source of cost data has appeared in 19 publications. The authors used 
the price of the corresponding service or product to estimate the cost of non-reimbursed 
products and services purchased by patients, as well as the cost of travel. 
3. Central Statistical Office 
In a total of 29 publications, the Central Statistical Office appears as a source of cost data, 
such as gross income in the case of productivity loss estimates and, in the case of 
measuring household health expenditure, the Central Statistical Office’s household panel 
survey was used (Baji et al., 2012a). 
4. Prices from other country 
In two publications, the price of a biological drug was estimated from a price from another 
country (UK) (Baji et al., 2018, Rencz et al., 2017). It certain cases, at the time of the 
analysis there was no officially established NHIFA price for the medicine in question, 
therefore a price from other countries may have been used. 
5. Expert opinion 
A reference to expert estimation as a source of cost data has appeared in two publications 
(Kovacs et al., 2014, Meszner et al., 2017). In this case, the price of the given item was 
not available to the authors, hence experts’ opinion was used. 
6. Not accurately identifiable data 
In 9.3% of publications (n = 7), the source of cost data was marked as multiple data 
sources, and could not be identified accurately (Bocskai et al., 2018, Coyle et al., 2018, 
Németh et al., 2018, Trapero-Bertran et al., 2018, Harangozó et al., 2008, Jakubczyk et 
al., 2016, Vallejo-Torres et al., 2018). These were mostly international research with the 
participation of Hungary. 
7. OECD average wage 
In one publication, the authors used the OECD average wage to estimate indirect costs 





8. Estimated based on patients’ answers 
In one of the selected publications, the amount of informal payment paid by the patients 





The costing perspective has been indicated for most of the publication. However, in 16 
(20%) publications, the perspective of costing was not indicated (Brodszky et al., 2011a, 
Baji et al., 2012a, Baji et al., 2012b, Daroczi et al., 2016, Fejes et al., 2019, Harangozó et 
al., 2008, Inotai et al., 2015, Iversen et al., 2015, József, 2006, Leal et al., 2016, Meszner 
et al., 2017, Péntek et al., 2007, Péntek et al., 2017c, Péntek et al., 2008, Tichopad et al., 
2013), their perspectives were identified during the analysis of the publications by 
categorizing the reported data: in nine cases it was societal (Harangozó et al., 2008, Inotai 
et al., 2015, Jakubczyk et al., 2016, Leal et al., 2016, Meszner et al., 2017, Péntek et al., 
2007, Péntek et al., 2008, Tichopad et al., 2013, Baji et al., 2012a), and in seven cases we 
could assume a payer perspective (Brodszky et al., 2011b, Bocskai et al., 2018, Daroczi 
et al., 2016, Fejes et al., 2019, Iversen et al., 2015, Kósa József et al., 2008, Péntek et al., 
2017c). 
Social perspective was used in a total of 38 publications (50.1%) of which 29 publications 
indicated the social perspective (38.7%) and in nine cases (12%), the social perspective 
was identified during the analysis of the data (Harangozó et al., 2008, Inotai et al., 2015, 
Jakubczyk et al., 2016, Leal et al., 2016, Meszner et al., 2017, Péntek et al., 2007, Péntek 
et al., 2008, Tichopad et al., 2013, Baji et al., 2012a). 
 Payer perspective was used by 37 publications (49.3%). Out of which 22 reported the 
perspective clearly (29,3%). In addition 2 publications indicated (2.7%) the  „healthcare 
system” (Coyle et al., 2018, Marada et al., 2016), 2 publications (2.7%) the „social 
insurance” (Horvath et al., 2014, Kárpáti et al., 2007), 3 publications (4%) the provider 
(Bodnár et al., 2010, Vallejo-Torres et al., 2018, Zemplenyi et al., 2016) and one 
publication (1.3%) indicated the government (Scuffham et al., 2006) as the perspective 
used. These were considered a payer perspective. In seven cases (9.3%) the perspective 
of the cost calculation was not indicated, and the payer perspective was identified during 
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the analysis of the data. (2011, Bocskai et al., 2018, Daroczi et al., 2016, Fejes et al., 










7.1. Health-related quality of life 
7.1.1. A Comparison of European Polish, Slovenian and British EQ-5D-3L 
value sets using a Hungarian sample of 18 chronic diseases 
 
We analysed the index values calculated with the four different sets of EQ-5D-3L values 
and the potential effects of this deviation in a total of 18 different diagnoses. Our analysis 
included several different diseases. Using cross-sectional samples from Hungarian patient 
populations (Rencz et al., 2016, Brodszky et al., 2009, Brodszky et al., 2010d, Érsek et 
al., 2010, Simoens et al., 2012, Pentek et al., 2013, Hever et al., 2015, Rencz et al., 2015a, 
Balogh et al., 2013, Tamás et al., 2014, Rencz et al., 2014, Péntek et al., 2007, Péntek et 
al., 2012b, Minier et al., 2010, Péntek et al., 2012c, Péntek et al., 2012a, Balogh et al., 
2014, Pulay et al., 2016). We analysed value sets which are often used or potentially used 
in health economics analyses in the Central and Eastern European region (Rencz et al., 
2016). Using patient-level data, we compared the utility values calculated with the four 
different value sets 
Previous studies has compared other TTO and VAS-based sets of values in several 
countries using, for example, population sampling, modelling, or analysis of a specific 
patient population (Mozzi et al., 2016, Endarti et al., 2018, Bernert et al., 2009) (Clemens 
et al., 2014) (Olsen et al., 2018). Furthermore, several other previous studies have 
compared value sets in each EQ-5D-3L profile (Kiadaliri, 2016, Golicki et al., 2010, 
Brooks et al., 2003). In our current research, we compared value sets that are based on 
two different methods (TTO and VAS) in several patient populations with different 
diagnoses. 
We found significant differences in our analysis by diagnosis, age group, and disease 
severity. The mean EQ-5D-3L index value difference was 0.265 in the PD diagnosis and 
0.187 in the 55-year-old group. Pairwise comparisons of disease burden (DB) yielded 
inconsistent results in comparing value sets based on different methodologies (TTO vs. 
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VAS). However, when comparing value sets based on the same methodology, we 
obtained consistent results. 
Our results confirm the hypothesis in previous research that methodological differences 
can be observed in the EQ-5D-3L value sets. (Olsen et al., 2018, Bernert et al., 2009). 
The discrepancy between the EQ-5D-3L value sets can lead to a significant discrepancy 
in utility values, thereby they may influence the assessment of health gains. Looking at 
an example, if a patient’s health status had moved from ‘22222’ (a moderate problem in 
all dimensions) to ‘11111’ (perfect health) (e.g. due to the effects of a new therapy), the 
QALY gain would be 0.685 with the Slovenian, and only 0.284 with Polish value set 
Moving from the worst possible health state (‘33333’) to the ‘22222’ state would mean a 
gain of 1,239 QALY with the Polish value set, but only 0.555 calculated with the 
European value set. 
Because of the significant differences observed between the value sets, the choice of value 
set can greatly affect the utility of a condition and thus influence the priorities set in health 
policy and funding decisions. 
These factors may be particularly important in the Central and Eastern European region, 
where in many cases local data are not available and health economics analysis often have 
to rely on external data sources (Gulácsi et al., 2016). The need to develop country-
specific value sets is increasing, as local value sets could better reflect the preferences of 
a given population (EuroQol, 2019).  
However, our research had certain limitations. The patients in our research do not always 
represent the entire patient population with a given disease. Further research involving 
several diseases would contribute to a better and deeper understanding of the differences 
in EQ-5D-3L index values established with the different value sets. 
In summary, it can be concluded that comparing different value sets on a sample of 
patients with chronic diseases, the importance of value set choice can be discovered and 






Public policy significance 
 
The choice of values is an important factor in the process of health economics analysis 
and health policy decision making. 
 
 Information on the utility of health conditions is essential for learning about individual 
and social benefits, and for planning a ‘fair’ resource allocation, as this will ensure that 
everyone receives care that meets their health needs in a transparent manner. The results 
of the research show that country-specific differences in quality of life cannot be ignored. 
In order to allocate health care resources in Hungary (similarly to the practice of 
developed countries) in accordance with the preferences of the Hungarian population, it 
is necessary to use an appropriate value set. This would ensure that healthcare meets the 
real needs of the population and that resource allocation decisions become more 
appropriate and transparent, and that information asymmetry could be controlled. 
 
7.1.2. A detailed analysis of ’not relevant’ responses on the DLQI in psoriasis: 
potential biases in treatment decisions 
 
In the present study, we analysed the incidence of NRR responses in the DLQI 
questionnaire among patients with psoriasis. Our results showed that the total DLQI 
score, PASI score, and several socio-demographic factors influenced how many NRR 
responses a patient indicated. 
More than one third (38.8%) of the patients reported at least one NRR response, and more 
patients with DLQI scores between 6 and 20 were candidates who reported an NRR 
response than those who did not. This suggests that certain areas appearing in DLQI are 
not significant in a significant proportion of psoriasis patients. Furthermore, since NRR 
responses receive a score of 0, a higher incidence of NRR responses would lead to a lower 
overall DLQI score. However, the results of our research show that the higher the total 
DLQI score, the more NRR responses patients mark. The inverse relationship between 
the high frequency of NRR responses and the total DLQI score and the number of NRR 
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responses suggests the existence of a validity problem. By omitting the questions with the 
NRR response and switching the resulting score to a scale of 0–30, the mean total DLQI 
score of the 166 patients with the NRR response increased from 7.23 to 8.94 (p <0.001). 
This increase was even more significant in the group over 65 years of age (n = 46), where 
the average would change from 7.41 points to 10.15 points (p <0.001). 
We observed that groups with certain socio-demographic characteristics were more likely 
to choose the NRR response. In our sample, these groups were women, the elderly, part-
time workers, and those with lower levels of education. 
Similarly, to previous studies, the NRR response was most common in sports, sexual 
difficulties, and work-related questions (Hahn et al., 2001, Mork et al., 2002, Twiss et al., 
2012, Ferraz et al., 2006, Khoudri et al., 2013, Mazzotti et al., 2005, Mayrshofer et al., 
2005). These questions are less relevant for older psoriasis patients than for younger ones. 
However, psoriasis is a lifelong, chronic disease, and, it is important that the outcome 
measures that are should be applicable to all ages. 
Our research had several limitations. Despite the large sample size, there were less than 
10 NRR responses for some questions and few patients reported more than 2 NRR 
responses. Furthermore, we do not have information on whether the patients in our sample 
were able to distinguish between NRR and “not at all” responses, which may be a 
misinterpretation of the previously highlighted problem with the questionnaire (Pentek et 
al., 2017).  
Two other studies also focused on the evolution of NRR responses in the DLQI 
questionnaire (Bashyam et al., 2019, Langenbruch et al., 2019). Langenbruch et al. 
analysed DLQI responses on a sample of 1240 patients with psoriasis. They found that 
48.7% of patients did not label any NRR response. Bashyam et al.  also highlighted the 
problem of choosing “not relevant” answers and stated that respondents may not always 
be able to distinguish that their illness prevents them from engaging in an activity or that 
they have no interest in doing the activity at all (Bashyam et al., 2019, Langenbruch et 






Public policy significance 
Disease-specific questionnaires are in many cases used to set up a therapeutic indication 
and to evaluate the benefits of a particular therapy. That is, the results of these 
questionnaires may influence how many and in what health condition (need) an individual 
will receive a particular therapy. In this research, we have seen that a patient’s access to 
therapy, in addition to his or her state of health, can be influenced by other socioeconomic, 
gender, age, and geographic characteristics of the individual. We do not consider this to 
be acceptable in the context of publicly funded healthcare, as it runs counter to the public 
policy objective of providing healthcare to the patient based on his or her needs. 
Access (which patient in which health state has access to a therapy) has an impact on 
cost-effectiveness and this data is extremely important when examining the budget impact 
of a given therapy. Cost-effectiveness and budget impact are influencing the decisions 
(on a national level whether) a given patient has access to a given medicine within the 
framework of publicly funded healthcare. 
 
7.1.3. The health state and productivity of the Hungarian general population 
 
The aim of our research was to assess the health status and productivity of the Hungarian 
population using standard methods. With an aging society and an increasingly efficient 
health care system, funding, the planning and provision of health services, and the 
sustainable employment of patients with chronic illnesses have become key priorities. 
Cost-effectiveness analysis based on local (country-specific) data are needed for decision-
making and evaluation of new technologies. In order to create sustainable employment 
and support the health policy decision-making process, local data, (regarding the health 
status of a population, labour productivity and knowledge on the relationship between the 
two factors) can be important information. We conducted a cross-sectional questionnaire 
survey among the Hungarian population, involving a representative sample. We used 
standard measures in our research. A total of 2,023 respondents participated in our 
questionnaire survey. 
The mean of the EQ-5D-5L index value was 0.92 (SD = 0.15) and the mean of the EQ-
VAS was 81.6 (SD = 17.4) among the participants. In WPAI, the average productivity 
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loss in other activities was 9.5% (SD = 21.0%), the average value of total productivity 
loss at work was 7.7% (SD = 20.9%), in the case of absenteeism and presenteeism mean 
values were 3.6% (16.4%) and 4.4% (14.2%), respectively. 
Wrona et al. analysed the decline in productivity due to health status (as measured by the 
WPAI-GH questionnaire) for the Polish population and their results were similar to those 
in other European countries. Examining groups with different incomes, it was found that 
total productivity loss at work was higher for higher-income households (Wrona et al., 
2010). In the present research, we found a significant relationship between the net 
monthly income of the household and the productivity loss in other activities. (r=-0,277, 
p=0,000). 
Mandel et al. also analysed the productivity loss in Hungary among people with 
inflammatory bowel disease and found that presenteeism and absenteeism were frequent 
(Mandel et al., 2014). In another study, also conducted in Hungary, Péntek et al. also used 
the EQ-5D and WPAI questionnaires to measure health-related quality of life and 
productivity among women with hyperactive bladder syndrome. Based on the results of 
Péntek et al. presenteeism was extremely significant among the patients studied (Péntek 
et al., 2012a). 
 
Public policy significance 
Therapies are extremely important not only for the elimination of clinical symptoms, but 
also for the restoration of an individual’s quality of life, social abilities, and ability to 
work. However, routinely collected data on these factors are not available, so in order to 
know the full benefits of therapies, it is necessary to examine them with health economics 
analyses. For optimal resource allocation and decision making, it is extremely important 
to fully understand the benefits of therapies. 
 
7.1.4. Characteristics and determinants of informal care in chronic diseases in 
Hungary: A comparative analysis 
 
In our research, we examined informal care among Hungarian patients by analysing 
patient-level data from our previous surveys of 14 chronic diseases. 
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A quarter (27%) of the patients received help from an unpaid helper, with an average of 
7.5 hours of informal care per week for the entire patient sample and a significant  
difference between diagnoses. In dementia, four inflammatory immunological diseases 
(RA, SSc, AP, and SM) and Parkinson’s disease, the highest rates of patients received 
informal care. (Figure 10.) The highest number of hours was also found in these diseases. 
(Figure 11.) The dependence of people with dementia on informal care is significant in 
Hungary as well, and our results are in line with international data (Costa et al., 2013). 
The difference in the results in dementia compared to other diagnoses may also be due to 
the fact that the time of informal care was measured with a dementia-specific 
questionnaire (the so-called RUD questionnaire), which recorded in detail the time spent 
on various activities and patient care and the number of care per week. Another difference 
is that in dementia, the relatives caring for the patient answered the questions, not the 
patients themselves. Carers may judge in differently what activities are included in 
informal care and how much time the carer (or carers) has spent on it. 
The methodology of informal care surveys is not uniform in the literature, to increase 
comparability, a disease-independent standard questionnaires (such as the iMTA 
Valuation of Informal Care Questionnaire - iVICQ) are increasingly used, and their use 
in Hungarian surveys should be considered (Hoefman et al., 2011). In Parkinson’s 
disease, informal care has been shown to be significant in other countries, averaging 10 
hours per week in the Czech Republic and Russia, but much higher hours have also been 
reported. (Bovolenta et al., 2017, Rodríguez-Blázquez et al., 2015). The inflammatory 
immunological diseases (RA, AP, SM, SSc) in our study typically had high disease 
activity, which partly explains the high informal care time (Brodszky et al., 2009, Minier 
et al., 2010, Péntek et al., 2012b, Péntek et al., 2007). It would be worthwhile to examine 
in future research how the costly but effective biological therapies (especially in RA and 
AP) has changed informal care use and its costs, for which, there is no routinely collected 
data available (Gulácsi et al., 2016). 
The average age and disease duration of those receiving informal care was only slightly 
higher than that of those not receiving informal care. More than twice as many women 
received informal care as men, while the proportion of women in the overall sample was 
only slightly higher. (Table 8.) Among the possible causes (e.g., difference in disease 
severity between men and women in the samples), it should also be considered that the 
surveys were based on patients’ self-reports except for dementia. Depending on what 
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activities someone performed before the illness (cooking, washing or cleaning), they may 
judge differently what is considered informal care (Hoefman et al., 2013). Although our 
research did not examine this, it is possible that a higher proportion of women became 
unable to carry out their previously normal household tasks due to the illness and 
therefore more of them considered that they needed help from others. 
We consider it important to emphasize that in our research we examined actual informal 
care and not the need for informal care. There may have been more patients in need of 
informal care, who did not receive any. Among those who did not receive informal care, 
there were more patients living alone, and it is possible that this was the reason some of 
them did not receive informal care. (Table 9.) 
Patients receiving informal care had significantly worse general health (EQ-5D-3L) than 
those who did not. (Table 9.) Among the dimensions of the EQ-5D-3L questionnaire, the 
largest differences were found in the Usual activities and Self-care dimensions between 
the two subgroups, with many more informal care recipients reporting some or severe 
problems in these areas. (Figure 12.) Our regression analysis confirmed our hypothesis: 
we found a significant relationship between informal care time and EQ-5D results. (Table 
10.) The gender of the patient also proved to be a significant determinant, and of the 14 
diseases examined, the association was significant in osteoporosis and Parkinson's 
disease. Applying an 8-hour care time limit per day, we obtained similar results. However, 
the variables included in the analysis only partially explained the informal care time. 
(Table 10.) Larger sample studies are suggested and exploring additional influencing 
factors (e.g., more detailed socio-demographic characteristics, caregiver health status and 
quality of life related, carer-caregiver relationship) are interesting areas for future 
research. 
Although informal care hours and patient’s health status measured with the EQ-5D 
questionnaire have been reported in a number of studies in the international literature, 
there are only a few publications analysing the relationship between the two. Brouwer 
and colleagues examined the relationship between patient quality of life, caregiver's 
ability to work and informal care in the Netherlands in RA (Brouwer et al., 2004). In 
Sweden similar studies were conducted in dementia (Neubauer et al., 2008, Wimo et al., 
2012). The studies with the highest number of cases was conducted in Germany by Rowen 
et al. (Rowen et al., 2016). In their analysis based on a questionnaire study of 44,500 
127 
 
participants, they found that a 0.1-point improvement in health measured by the EQ-5D 
index score could reduce informal care time by less than 1 or even more than 2 days over 
a six-week period, depending on the modelling method. Thus, the time gained by 
caregivers by improving the patient's condition is significant, hence it is worthwhile to 
conduct further research in this field and at the same time examine the changes in the 
quality of life of the caregivers. 
The limitations of our research should also be mentioned. Only those local studies where 
patient-level data were available were included in our analysis, although to the best of our 
knowledge, other Hungarian research groups did not report any surveys containing both 
informal care and EQ-5D-3L data. Clinical areas that may be important for informal care 
have not been studied due to lack of data ─ such as oncology, end-of-life conditions, 
diabetes in old age, hearing loss, COPD ─, it is recommended to conduct surveys in these 
diseases in the future. Surveys with the five-response, more sensitive version of the EQ-
5D questionnaire (EQ-5D-5L) may provide a more accurate picture of the relationship 
between informal care and patients’ health status (Angelis et al., 2016b, Lopez-Bastida et 
al., 2016a, Lopez-Bastida et al., 2016b, Kuhlmann et al., 2016, Cavazza et al., 2016b, 
Péntek et al., 2014, Péntek et al., 2016a, Rencz et al., 2014, Cavazza et al., 2016a). It 
would be worthwhile to further examine patients' expectations, the relationship between 
disease stages and informal care in larger samples, including standard disease-specific 
measures (Herédi et al., 2014, Rencz et al., 2015a). In our research, we did not examine 
the access and use of formal care (health and social care, residential homes, day care 
centres), which may also influence the informal care needs and burden. 
We believe that despite these limitations, our research provides a valuable summary and 
analysis of informal care and its determinants in a wide range of chronic diseases in 
Hungary. Based on our results, the burden on the family, especially for diseases leading 
to disability, is very significant. Changes in the life of a patient's family during treatment 
─ including the quality of life of carers and the costs of informal care ─ are worthwhile 
and necessary to assess in order to get a complete picture of the disease burden and the 
results achieved with successful treatment. 
Public policy significance 
Our research provides data for further health economics analysis, as well as highlights the 
importance of research on informal care, methodological challenges, and significant areas 
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of research that have not yet been explored. From a public policy perspective, the disease 
burden of each health problem needs to be examined from a societal perspective. We need 
to identify and measure all the factors that contribute to the social burden and may be 
relevant. Typically, informal care may be overlooked, but cause a significant social 
burden. 
We hope that our analysis will give momentum to research on informal care in Hungary, 




7.2.1. Cost of informal care in chronic diseases in Hungary: A comparative 
analysis 
 
The results of our study clearly confirmed that the cost of informal care is very high in 
Hungary, similarly to the international data. The research used in the present study 
included patients who had received outpatient care or hospitalization due to their illness, 
and the patient samples represented a group of these patients. 
However, to calculate the exact amount of informal care cost, we would need information 
on what extent our study results can be generalized to the entire population of those with 
the diseases we studied. This information is not available in the databases of routinely 
collected data (NHIFA and other public health databases), and we would need this to 
calculate the amounts reliably (KSH, 2009, OECD, 2017). There are various surveys 
reporting data on how many people provide or receive informal care in the elderly 
population, in Hungary. However, these do not contain data related to specific diagnoses 
or health conditions, so they are not suitable for estimating the disease burden caused by 
different diseases in health economics analysis. 
 
Measuring the cost of informal care also appears in international studies. Rheumatoid 
arthritis also appeared in a systematic literature review by Krol et al. The authors found 
results on a wide range of costs for informal care for rheumatoid arthritis patients (569 




Knowledge of these amounts is necessary for health policy to be able to assess the real 
social cost and importance of diseases. Without knowledge of the costs of informal care, 
it is not possible to make informed health policy and funding decisions. Surveys clearly 
show the population and patients’ need for informal care. Increasing life expectancy and 
caring for an increasing number of chronic patients are predictably in the future. However, 
the number of people living in the same household is not high and is expected to decrease, 
which is why the number of informal providers is expected to decrease.  
 In the absence of informal care, the care must be provided by the public or private 
providers, i.e., formal health care, which anticipates significant additional capacity, 
labour, and cost demands. It should be mentioned that there is still a significant shortage 
of specialists in the healthcare and social sectors, and it does not seem possible to involve 
a larger number of specialists. 
In the future, it would be necessary to observe the need for informal care in Hungary in 
order for the need for care and financing to be known and plan for care needs and 
financing, either for the state or for insurers. Furthermore, it would be useful to also 
analyse the unfulfilled needs, and thus to identify the groups, including the most 
vulnerable patients, who do not receive adequate care. 
Among the limitations of our analysis, it should be mentioned that the national estimate 
was made on the assumption that the patients included in the research are well 
representative of all patients in Hungary suffering from the studied disease. In the studies, 
we did not take into account that a patient may have multiple chronic illnesses, so we 
could overestimate the cost. The extent of the bias is invaluable without further research. 
Another possible bias is that we only measured the informal care received, we have no 
information on patients who needed informal care, but did not receive any. Because of 
this, we may have underestimated the actual costs. As a further limitation, it is important 
to mention that the number of hours of informal care was derived from studies conducted 
in different years, and the was taken into account when calculating 2017 costs. However, 
over time, the treatment of many diseases may have changed significantly, and the 
introduction of new effective therapies may have modified the number of hours of 
informal care in some patient subgroups (e.g., patients with rheumatoid arthritis now 
treated with biologics). 
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Public policy significance 
Without full knowledge the specific costs, no proper public policy decision can be made. 
Based on our results, we believe that the estimated costs are high and the cost of informal 
care is significant in Hungary. Thus it is necessary to learn about the real social burden, 
make appropriate health policy decisions and develop sustainable financing. 
 
7.2.2. Cost-of-illness studies in nine Central and Eastern European countries 
 
As a result of our literature search, we identified 58 studies (containing 83 country-
specific results) that reported disease cost (COI) data for Austria, Bulgaria, the Czech 
Republic, Croatia, Hungary, Poland, Romania, Slovakia, Slovenia. the most commonly 
discussed clinical area was endocrine, nutritional, and metabolic diseases. The reporting 
of costs in euros was dominant, which may suggest researchers in the region find it 
important to make their results available for international comparison. 
The issue of transferability arises in many cases, however, the methodological 
heterogeneity discovered in the 58 studies examined may make this significantly more 
difficult in the CEE region. To assess the quality of the publications, we examined the 
description of the methodology used. We consider it important to point out that the data 
sources of resource use and the year of cost calculation were reported in almost all 
publications (98% and 95%, respectively), many other extremely important indicators 
were reported in far fewer cases. 
The perspective used was indicated in 78% of the publications, the approach used to 
measure indirect costs was 77%, the methodology of cost calculation was 64%, at least 
one unit cost was 42%, and the method of evaluating informal care was 31%. 
A review of recent analyses in Austria found that the year of prospecting and costing was 
not reported in 60% and 25% of the research. The differences can be explained by the 
selection of “gray literatures”. Mayer et al. discussed 93 economic analyses, 14 of which 
were disease cost surveys. Furthermore, of the 93 studies, 23 were non-indexed and 12 
were non-peer-reviewed publications (Mayer et al., 2017). 
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Different studies discussing a disease have shown large differences across countries, but 
comparability varies from study to study. 
The methodologies used were very different in many cases, and the differences in the 
samples included in the research (sample size, average age of the participants in the 
sample, diagnosis, available therapies) should also be taken into account in many cases. 
Differences in unit costs can also contribute greatly to differences in results (Mayer et al., 
2017). 
In bladder cancer research, for example, the cost of a hospital day was 7 times as high in 
Austria (495 EUR) as in Romania (67 EUR) (Leal et al., 2016). Methodological 
differences such as incidence vs. the prevalence-based research methodology also hinders 
cost comparisons. Just as the incidence-based article on prostate cancer by Brodszky et 
al. is not comparable to the prevalence-based article by Inotai et al., which is also 
discussing prostate cancer, despite the fact that both are from Hungary (Brodszky et al., 
2017, Inotai et al., 2015). Due to the differences in health systems, we can also observe 
very different costs results in different countries. 
During the past two decades, several publications were focusing on the question of 
transferability (Nixon et al., 2009, de Pouvourville et al., 2005, Drummond et al., 2003, 
Barbieri et al., 2010, Mandrik et al., 2015, Gulácsi et al., 2014a). Currently, health 
Economics and HTA Directives in the Central and Eastern European region contain either 
very limited or no directive on transferability and adaptations. Therefore, the 
development of a directive on the conduct of cost of illness studies would be extremely 
valuable for the countries of the region (Gulácsi et al., 2014a).  
Our present research has several limitations. We conducted a systematic literature search 
to identify relevant publications, however, the possibility arises that relevant literature 
has not been identified and selected. Some disease cost results may not appear in our 
review because we have excluded conference abstracts and reports from our search. 
Manual searches of non-indexed journals were performed in only three countries. An 
additional limitation is that we did not use a comprehensive checklist, as to our knowledge 
this was not available for cost of illness studies in English or Hungarian. This may skew 
our conclusions about the quality of the studies, but we believe that the study 




Public policy significance 
Due to the differences of health systems, we can also observe very different cost results 
in the different countries. In order to make financing decisions, it is necessary to carry out 
analysis in accordance with the specifics of the given country. Limited transferability 
(cost data cannot be transferred from one country to another) and legal requirements also 
point to the need to use local data. 
 
7.2.3. Hungarian cost library 
 
We conducted a literature review of health economics publications in Hungary and 
identified the unit costs reported. The need to develop a cost library (healthcare cost 
catalogue) in Hungary has already came up in many cases since the accession to the EU 
in 2004, as the use of local data is extremely importance in all health economics analyses. 
A professional description of the creation of the ‘cost-library’ in Austria was published 
by Mayer et al. They identified cost elements to be included in the “cost-library” during 
the analysis of published sources. In their systematic literature search (covering the period 
2004-2015), Mayer et al. selected a total of 93 publications in German and English, 87% 
of which were journal articles; according to the clinical area, the diseases of the ICD main 
group “Diseases of the circulatory system” appeared most often (n = 15). Of the selected 
articles, 14 were cost of illness analysis. The difficulties (and importance) of the work are 
shown by the fact that Mayer and colleagues highlight that 60% of the articles did not 
clearly describe the research perspective, more than a quarter did not indicate all sources, 




We conducted a literature search in order to identify and collect unit costs for Hungary. 
Our search currently only covered publications published in Hungary. In the future, it 
may be advisable to expand our data with similar data from Central and Eastern European 
countries. In this case, our assumption is that the health cost data of countries with similar 
social and economic conditions are closer to each other and can be utilized better than 
those of countries further apart in this respect. 
Public policy significance 
One of the most significant elements of healthcare decision-making is the optimization 
of resource allocation. However, this requires knowledge of the cost and societal burden 




8. NEW RESULTS 
 
 
8.1. Health-related quality of life  
 
8.1.1. A Comparison of European Polish, Slovenian and British EQ-5D-3L 
value sets using a Hungarian sample of 18 chronic diseases 
 
We found methodology based differences between the value sets. The choice of value set 
may affect utility of health states significantly and could affect health policy decision 
making.  
 
8.1.2. A detailed analysis of ’not relevant’ responses on the DLQI in psoriasis: 
potential biases in treatment decisions 
 
 
We were the first to report the detailed analysis of the ’not relevant’ responses on the 
DLQI questionnaire. We found that the incidence of ’not relevant’ responses is common. 
They are more likely to occur among older, less educated, and female patients, so these 
patients may be at a disadvantage due to the specifics of DLQI scoring. 
 
 
8.1.3. The health state and productivity of the Hungarian general population 
 
  
We assessed the Hungarian general populations ICECAP-A and ICECAP-O scores 






8.1.4. Characteristics and determinants of informal care in chronic diseases in 
Hungary: A comparative analysis 
 
For the first time in Hungary and in the region, we assessed and published results on the 
use of informal care and its relation to health-related quality of life in 14 chronic diseases, 




8.2.1. Cost of informal care in chronic diseases in Hungary: A 
comparative analysis 
We analysed the informal care cost in Hungary and in the region on a large sample and 
found that these are significant and comparable to that of other countries.  
 
 
8.2.2. Cost-of-illness studies in nine Central and Eastern European 
countries 
 
We analysed the relevant publications and compared the cost of illness results across 
several countries in the Central and Eastern European region. The results of our analysis 
show that the generally accepted opinion that the disease burden results of the countries 
of the region are transferrable between countries is not realistic. This is due to a high 
degree of methodological heterogeneity and a lack of standards. 
 
 
8.2.3. Hungarian cost library 
 
Due to the need for utilizing local data, we created the fourth country specific cost library 








In the dissertation I wanted to examine the role of disease burden and quality of life in in 
health care decision making, which is a particularly important issue, as the disease burden 
and costs of chronic diseases are significant and growing not only at the individual but 
also on a societal level. 
The economics of chronic diseases is a particularly important issue from the health 
policy’s’ point of view, as knowledge of costs and outcomes is needed to create 
sustainable financing and to achieve optimal resource allocation. Assessing the burden of 
disease also provides essential information for health policy decision makers when 
analysing the cost-effectiveness of therapies. 
The research areas discussed in the dissertation and the data included in these research 
are therefore absolutely necessary for the preparation of financing decisions in order to 
optimally organize the allocation of resources. 
In many cases, we do not have enough information about some of the burdens such as the 
cost of informal care provided by relatives or the cost of labour productivity loss. It is 
important to point out that these data cannot be found in routinely collected databases, so 
the total social burden of their costs and thus of the diseases is not known. 
Another important factor in relation to illness is quality of life. Data on quality of life and 
the social dimension of quality of life are also not collected in routinely created databases, 
which raises the problem of not being able to fully measure the outcome of therapies, as 
therapies often not only aiming to eliminate clinical symptoms but to improve quality of 
life and rebuild skills. Data on all this can only be learned from this health economics 
research. 
In the dissertation we discussed the research covering the field of quality of life 
measurement and cost calculation: During the examination of the quality of life we 
examined the general EQ-5D and a disease-specific questionnaire, and the quality of life, 
social skills and productivity loss in the Hungarian general population. In the dissertation, 
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we paid special attention to the analysation of the use and costs of informal care, and we 
found that these are extremely significant in Hungary as well. 
In order to examine the cost of diseases, the dissertation presents an overview of cost of 
illness studies in the region, i.e. in nine Central and Eastern European countries. Based 
on the results, we can conclude that the usability and transferability of the cost data 
published in the region is strongly limited, as we encountered great methodological 
heterogeneity in the publications. 
The Hungarian cost library also plays a significant role in learning about the costs of 
illness and the financing of health care. In Hungary, the almost exclusive source of cost 
data is currently the databases of the National Health Insurance Fund (which do not 
contain a lot of data that are essential for health economic analysis (e.g. direct non-health 
costs, indirect costs, disease severity outcome). For this reason, there is a great need for 
a catalogue of healthcare costs in Hungary, which includes a wider range of costs. In the 
dissertation, the process of developing the Hungarian health care online cost catalogue 
was published: we conducted a literature search in order to identify the relevant 
publications. Using the 75 selected publication, we developed the Hungarian cost 
library’s structure and the analysed characteristics and quality of the publications. 
The use of health economics results in health policy decision-making is significantly 
hampered by the fact that the methodology used in the publications is extremely 
heterogeneous, not always fully described, the source of the data is often not clearly 













10.  ANSWERS TO THE HYPOTHESES 
 
 
10.1. Health-related quality of life 
 
A Comparison of European Polish, Slovenian and British EQ-5D-3L value sets using a 
Hungarian sample of 18 chronic diseases 
Hypothesis 1. 
We assume that the European, Polish, Slovenian and UK EQ-5D-3L value sets do not 
differ significantly 
Our results suggest that the value sets show significant differences, we reject Hypothesis 
1. 
 
1.1. We assume that applying different value sets in the 18 chronic diseases that we 
examined, the health policy and funding decisions based on the results do not differ 
significantly in different countries. 
Our results suggest that the use of different value sets would cause differences in health 
policy decision making, hence we reject Hypothesis 1.1. 
A detailed analysis of ’not relevant’ responses on the DLQI in psoriasis: potential biases 
in treatment decisions 
Hypothesis 2. 
We assume that the ’not relevant’ answers of the DLQI questionnaire differ in the 
different demographic groups.  
Our research results show that there may be significant differences in not relevant 
responses between groups with different demographic and socioeconomic 




2.1. We assume that the effect of the differences on medical decision-making and resource 
allocation can be observed. 
Our results suggest that the effect of the differences on medical decision-making and 
resource allocation can be observed and significant, hence we accept Hypothesis 2.1. 
 
The health state and productivity of the Hungarian general population 
Hypothesis 3. 
We assume that the health status and work productivity of the Hungarian general 
population can be adequately measured by the standard questionnaires we used. 
The health status and work productivity of the Hungarian general population can be 
adequately measured by the standard questionnaires we used, hence we accept 
Hypothesis 3. 
 
Characteristics and determinants of informal care in chronic diseases in Hungary: A 
comparative analysis 
Hypothesis 4. 
We assume that the characteristics and determinants of informal care in Hungary are 
similar to what can be observed in other countries.  
Our results suggest that the characteristics and determinants of informal care in Hungary 
are similar to the results in other countries, hence we accept Hypothesis 4.  
 
10.2. Costing 
Cost of informal care in chronic diseases in Hungary: A comparative analysis 
Hypothesis 5. 
We assume that the social burden and cost of informal care is very significant in Hungary 
as well, in accordance with international experience. 
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Our research results show that the social burden and cost of informal care is significant 
in Hungary and is in line with international experience. In Hungary, this burden is lower 
in absolute terms than in the higher GDP/capita countries, but in similar proportions, 
accordingly we accept Hypothesis 5. 
 
Cost-of-illness studies in nine Central and Eastern European countries 
Hypothesis 6. 
We assume that the costs of illness in Hungary are similar to those in other Central and 
Eastern European countries. 
Our research results show that the costs of illness in Hungary are similar to other Central 
and Eastern European countries, so we accept Hypothesis 6. 
 
6.1. We assume that in Hungary the cost data published in other Central Eastern European 
country can be utilized and transferred better than the cost data originated in countries 
with high national income.  
The results of our research show that the usability and transferability of cost data 
published in Central Eastern European countries is strongly limited, we assume that the 
results of other countries (e.g. UK) can be better transferred, accordingly we reject 
Hypothesis 6.1. 
 
Hungarian cost library 
Hypothesis 7. 
We assume that a Hungarian cost library can be created as sufficient local data is 
available. 
Our results suggest that sufficient local data is available in Hungary to create a local 
cost library, hence, we accept hypothesis 7. 
 
7.1. We assume that the Hungarian cost library can contribute to the development of 
appropriate and sustainable health care financing decisions. 
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The data needs of the current health care reforms show that such data are needed more 
than ever before, therefor we accept the hypothesis 7.1. 
 
7.2. We assume that the Hungarian unit costs and cost are significantly different than 
what can be observed in high-income countries 
Our research results show that Hungarian unit costs and costs differ significantly from 
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